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ABSTRACT
Engineering Cell-Free Systems for Vaccine Development,
Self-Assembling Nanoparticles and
Codon Reassignment Applications
Mark Thomas Smith
Department of Chemical Engineering, BYU
Doctor of Philosophy
This dissertation reports on the technology of cell-free protein synthesis (CFPS)
including 1) stabilized lyophilized cell-free systems and 2) enhanced heterogeneous cell extracts.
This work further considers applications of CFPS systems in 1) rapid vaccine development, 2)
functional virus-based nanoparticles, 3) site-specific protein immobilization, and 4) expanding
the language of biology using unnatural amino acids.
CFPS technology is a versatile protein production platform that has many features
unavailable in in vivo expression systems. The primary benefit cell-free systems provide is the
direct access to the reaction environment, which is no longer hindered by the presence of a cellwall. The “openness” of the system makes it a compelling candidate for many technologies. One
limitation of CFPS is the necessity of freezing for long-term viable storage. We demonstrate that
a lyophilized CFPS system is more stable against nonideal storage than traditional CFPS
reagents. The Escherichia coli-based CFPS system in this work is limited by the biocatalytic
machinery found natively in E. coli. To combat these limitations, exogenous biocatalysts can be
expressed during fermentation of cells prepared into extract. We demonstrate that simple
adjustments in the fermentation conditions can significantly increase the activity of the
heterogeneous extract.
Towards virus-based particles and vaccines, we demonstrate that the open nature of
CFPS can be utilized for coexpression of virus proteins and self-assembly of virus particles. This
technique allows for the rapid production of potential vaccines and novel functional virus-based
nanoparticles.
Unnatural amino acids expand the effective language of protein biology. Utilizing CFPS
as an expression system, we demonstrated that the incorporation of a single specific unnatural
amino acid allows for site-specific immobilization, thus stabilizing the protein against elevated
temperatures and chemical denaturants. Current unnatural amino acid incorporation technologies
are limited to one or few simultaneous incorporations and suffer from low efficiency. This work
proposes a system that could potentially allow for upwards of 40 unnatural amino acids to be
simultaneously incorporated, effectively tripling the protein code.
These projects demonstrate the power and versatility of CFPS technologies while laying
the foundation for promising technologies in the field of biotechnology.
Keywords: Mark Smith, cell-free protein synthesis, virus-based particles, Foot-and-mouth
disease virus, unnatural amino acids, codon reassignment
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1

INTRODUCTION

In vitro or cell-free systems are biologically-based reaction systems that harness the power
of cells without many of the inconveniences of such. These systems are produced by extracting
and/or purifying cellular machinery and placing the machinery into an environment sufficiently
mimicking intracellular conditions to undertake biological reactions. There are myriad powerful
tools in the subset of cell-free systems, such as cell-free protein synthesis (CFPS), cell-free
transcription (CFT) and polymerase chain reaction (PCR). This work has employed all of these
techniques with the primary focus on CFPS. The diverse and powerful potential of cell-free
systems make them compelling tools in the belt of the chemical engineer.
The dominant advantage of CFPS over in vivo protein production systems is the open,
unhampered access to the reaction environment. By extracting the cellular machinery, the cell
membrane no longer presents a barrier to the reaction. The access allows for facile manipulation
and monitoring of the reaction environment. Aspects of the reaction such as pH, salt content, and
redox potential are readily controlled (1-4). Reaction content can be controlled such as genetic
material (5-7), catalytic enzymes (8-11), chaperones (2,12), energy sources (13-16), and cofactors.
Cell-free systems have many other propitious features. CFPS reactions harness the entire
reaction volume for synthesis, unlike production in cell fermentation, where only 5-20% of the
fermentation volume (intracellular space) is actively participating in synthesis (17). CFPS is also
instantly scalable, in other words, the reactions do not need serial fermentations to get to a final
fermentation volume, rather they can be immediately initiated at scale (18-20). Reaction volumes
1

are broadly scalable, from 15 microliters up to 100 liters (18). Also, cell-free systems have high
specific yields and very low levels of byproducts (21). This specificity eases the burden of
production, purification, and analysis. Cell-free systems can also be assembled in high-throughput
formats that rely on direct expression from PCR products known as linear expression templates
(LETs) (7,22,23).
The many favorable features of CFPS make it a compelling tool for a broad range of
applications, such as protein engineering, high throughput screening, and microarrays (6,24-26).
Many therapeutic and diagnostic oriented applications have been pursued such as functional
antibodies (27), therapeutic proteins (28), and functional genomics (29,30). CFPS allows for
applications that would otherwise be difficult or impossible in vivo such as targeted NMR-based
structural analysis (31), incorporation of unnatural amino acids (8,20), and production of toxic
proteins (19,32).

1.1

Scope of the Projects
Although there are many CFPS applications and systems reported, there remains many

promising yet unexplored CFPS technologies and applications. In this work, we aimed to improve
and demonstrate the utility of CFPS systems for some of these applications. We consider these
projects in 2 primary divisions: 1) enhancement of CFPS technology and 2) application of CFPS
technology. Detailed background information for each research project is found within each
chapter.
In summary, the objectives of this work are:
1. To produce more stable and accessible reagents for CFPS.
2. To enhance preparation methods of extracts containing exogenous catalysts that aid in
protein synthesis.
2

3. To develop a rapid vaccine production platform based on CFPS.
4. To produce novel functionalized virus-bases nanoparticles.
5. To enhance protein stability through site-specific immobilization.
6. To expand the language of biology through native codon reassignment.

1.1.1

Enhancing CFPS technology: Lyophilization, Alternative Fermentation
Lyophilized CFPS: CFPS systems have many compelling features not found in vivo.

However, one shared trait is the necessity to store the samples long term below freezing for
stability. The storage requirements restrict applications that require long-term transport or nonideal storage, such as pharmacy-on-a-chip or onsite vaccine production. In efforts towards a more
robust system, we produced a lyophilized CFPS system. This system maintained more long-term
synthesis viability than standard aqueous systems under non-ideal storage conditions.
Furthermore, our lyophilized system demonstrated reduced residual contamination. The
development of lyophilized CFPS system reduces the cost of storage, simplifies storage procedure,
and expands the viable applications of CFPS technologies.
Alternative Fermentation Conditions: Some CFPS systems require supplemental or
exogenous elements to make them functional. For example, expression of the large protein
Candida antartica Lipase B (CalB) in Escherichia coli-based cell extract results in low soluble
yields unless excessive exogenous chaperone proteins (GroEL/ES) are introduced. Due to the open
nature of CFPS, GroEL/ES can be added directly to the reaction mixture, however, this requires
significant preparation in form of cell fermentation, lysis, protein purification, and protein analysis.
To avoid these time- and cost-intensive efforts, we produced and optimized an improved system
that relies on expressing the supplemental element during extract preparation. This system was
based on basic adjustments in the fermentation of cells to be prepared into extract. The resulting
3

extracts were capable of producing upwards of 5x the amount of soluble CalB compared to the
direct addition of GroEL/ES.

1.1.2

Applying CFPS Technology: Vaccines, Nanoparticles, Unnatural Amino Acids
Rapid Vaccine Production: Vaccines typically consist of an immunogenic element that is

introduced into the host to induce adaptive immunity. For virus-directed vaccines, these elements
are often the virus itself, either in an attenuated form or inactivated. Use of the virus itself raises
concerns of potential disease caused by vaccination using viruses that are insufficiently attenuated
or inactivated. Recombinant protein technologies allow this issue to be avoided by producing only
the proteins necessary for immunogenicity while remaining insufficient for pathogenicity. Using
Foot-and-mouth disease virus as a model virus target, we worked towards a rapid vaccine
production system that utilizes CFPS as its protein production system. This system would allow
for onsite vaccine production and deployment, thus reducing the costs and safety concerns
surrounding the production of vaccine for worldwide viral epidemics, such Foot-and-mouth
disease.
Novel Functional Virus-based Nanoparticles: The basic principles of recombinant virus
protein production found in vaccine production could also produce novel nanoparticles. Viruses
typically consist of nucleic acids encased in a nanometric protein-shell, known as a capsid. Capsid
proteins typically self-assemble into the full capsid shell using cues from other capsid proteins or
short sequences of the nucleic acids. Harnessing these propitious traits, we produced a novel virusbased nanoparticle based on the bacteriophage Qβ. These nanoparticles are thermostable up to
70°C and can form disulfide bonds between capsid proteins. In addition, we demonstrated that the
toxic protein A2 can be incorporated in a surface-accessible manner at a level of 1 A2 per 1
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nanoparticle. These particles could have applications in imaging techniques or could be similarly
engineered for myriad diverse applications.
Stabilized, Site-specifically Immobilized Protein: Immobilizing proteins has long been
used for improving the stability of proteins. The most robust protein immobilization techniques
are covalent. However, precisely controlling which location on the protein covalently binds to a
surface is complicated by the naturally limited pool of only 20 amino acids building blocks.
Therefore, covalent immobilization techniques that target residue side-chains often present
multiple immobilization possibilities for a single protein. Unnatural amino acids provide a unique
functional group that can be designed to react orthogonally to other residues. These unnatural
amino acids can be introduced virtually anywhere within a protein, allowing for rational
engineering of the recombinant protein with the unnatural amino acid incorporated. Using this
technology, we demonstrate that a green fluorescent protein can be site-specifically immobilized.
This immobilization enhances the thermostability and robustness of the protein against chemical
denaturants. The technology has promising applications in development of robust and reusable
biosensors and biocatalysts.
Expanded Language of Biology: The introduction of unnatural amino acids effectively
expands the langue of protein biology, allowing for diverse applications such as the above
mentioned protein immobilization. Current technologies rely on the stop-codon reassignment or
frame-shift codons to incorporate the unnatural amino acid. Stop-codon reassignment is restricted
by the existence of only 3 stop codons, one of which must be used to terminate the peptide
synthesis. Furthermore, reassigned stop codons will frequently be read as stop, resulting in
premature peptide termination. Frame-shift codons suffer from the trouble of competing against
the tRNA for the 3-base codon. Due to the inefficiencies, these techniques have only been
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successful at incorporating a few different unnatural amino acids simultaneously at low efficiency.
We propose the novel method of complete native codon reassignment for unnatural amino acid
incorporation. To accomplish this, we remove effectively all of the native tRNA and replace it
with a synthetic minimal set of tRNA. This technology could potentially allow up to 40 unnatural
amino acids to be incorporated simultaneously, doubling the canonical set of amino acids.

1.2

Outline
The bulk of this dissertation constitutes modifications of publications that I lead,

developed, and authored, in several cases with significant help from other students as described in
more detail in each chapter. These are summarized below.
Chapter 2: Stabilized Cell-free Systems through Lyophilization
This chapter is an adaptation from the article entitled “Lyophilized Escherichia coli-based
Cell-free Systems for Robust, High-density, Long-term Storage” published in the journal
Biotechniques, April 2014.
Chapter 3: Alternative Fermentation Conditions for Extract Preparation
This chapter is an adaptation from the article entitled “Alternative Fermentation Conditions
for Improved Escherichia coli-based Cell-free Protein Synthesis Requiring Supplemental
Components for Proper Synthesis” published in the journal Process Biochemistry, February 2014.
Chapter 4: Rapid Vaccine Development and Production
This chapter discusses the impetus behind a rapid vaccine development system based on
CFPS and the results of the developing technology and is in part an adaptation from a review
article entitled “Foot-and-mouth Disease: Technical and Political Challenges to Eradication”
submitted to Vaccine Journal, February 2014.
Chapter 5: Novel Virus-based Nanoparticles
6

This chapter is an adaptation from the article entitled “The Incorporation of A2 Protein to
Produce Novel Q[beta] Virus-like Particles using Cell-free Protein Synthesis” published in the
journal Biotechnology Progress, March 2011.
Chapter 6: Stabilized Protein Through Site-specific Immobilization
This chapter is an adaptation from the article entitled “Enhanced Protein Stability Through
Minimally-invasive, Direct, Covalent and Site-specific Immobilization” published in the journal
Biotechnology Progress, January 2013.
Chapter 7: Expanding the Language of Biology: Sense Codon Reassignment
This chapter discusses the impetus behind expanding the language of biology based on
CFPS and the results of the developing technology and is in part an adaption from the article “Cellfree Unnatural Amino Acid Incorporation with Alternative Energy Systems and Linear Expression
Templates” published in New Biotechnology, January 2014.
Chapter 8: Conclusions and Future Work
This chapter briefly summarizes the novel work performed as part of this dissertation and
suggests future impacts and directions for ensuing works.
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2

STABILIZED CELL-FREE SYSTEMS THROUGH LYOPHILIZATION

This chapter is an adaptation from the article entitled “Lyophilized Escherichia coli-based
Cell-free Systems for Robust, High-density, Long-term Storage” accepted to BioTechniques for
publication in April 2014. This work was developed and lead by myself with the help of Scott
Berkheimer and Chris Werner.

2.1

Introduction
Cell-free protein synthesis (CFPS) is a powerful in vitro transcription/translation tool for

rapid and efficient production of recombinant proteins. Compared to in vivo protein production,
directly accessible cell-free systems provide superior control over the synthesis environment,
higher product selectivity, and faster expression of recombinant genes (7,17,33). These attributes
make cell-free technology an excellent platform for high-throughput recombinant expression and
synthetic biology technologies (23,33-37). Exploiting the benefits of CFPS, myriad proteins have
been produced such as virus-like particles (1,19), proteins containing unnatural amino acids
(8,9,38), cytotoxic proteins (19), and a variety of biocatalytic enzymes (12,39).
CFPS has been successfully demonstrated with biochemical machinery extracted from
many different organisms and cells types, such as wheat-germ, rabbit reticulocytes, insects, yeast,
and HeLa cells (35,40). In this work, we focus on the most prevalent, least expensive, and generally
highest yielding cell-free system, which is based upon Escherichia coli extract (35).

9

A common practice in CFPS is to store prepared cellular extracts at -20 oC or -80 oC prior
to use in efforts to maintain protein synthesis viability (8,41-43). Such practice necessitates fairly
significant capital equipment investment in the form of low or ultralow temperature freezers, their
maintenance, emergency backup freezers, and emergency backup power. These storage
considerations are particularly cumbersome when stockpiling large quantities of extract for
applications such as rapid vaccine and/or therapeutic production in response to a pandemic. A
further limitation of storing the CFPS extracts below freezing temperatures is the inability to easily
transport for mobile use applications.
One possibility to improve CFPS extract storage efficiency and utility is to lyophilize the
extracts. Lyophilizing or freeze-drying simple protein solutions is a common process to remove
the volatile liquids, leaving behind a protein powder. This technique reduces the storage volume
and should slow the rate of protein degradation. We hypothesized that lyophilizing E. coli cell
extracts would similarly reduce storage volume and potentially allow for longer shelf-life at
temperatures above -80oC. Lyophilized cell-free systems are commercially available and previous
studies have reported successful synthesis of various proteins using rehydrated lyophilized extracts
(44-48). However, a straightforward method to produce a lyophilized E. coli-based cell-free
system has yet to be detailed in literature. Furthermore, the impact of lyophilization and storage at
non-standard temperatures on protein synthesis performance has yet to be described. Here we
report a straightforward method for lyophilizing E. coli extract for CFPS using standard
machinery. The lyophilized extracts allow for higher density storage and maintain a higher protein
synthesis viability at non-standard storage temperatures than aqueous extracts. This simple method
provides a viable and convenient alternative to traditional storage strategies by reducing storage
costs, protecting extract viability and promoting CFPS accessibility.

10

2.2

2.2.1

Materials and Methods

Cell Extract Preparation
Cells were grown and extracts prepared as previously described (7,49). All growth stages

were performed at 37oC in LB media at 280 rpm. Briefly, Escherichia coli strain BL21-Star™
(DE3) (Life Technologies, New York) was inoculated overnight in 5 mL volumes. Overnight
growths were transferred to 500 mL baffled shake flasks containing 100 mL media. The
intermediate growths were monitored to an OD600 of 2 and transferred to 2.5 L Tunair shake flasks
(IBI Scientific, Iowa) containing 1 L of media. Growths were induced with 1 mM IPTG
(GoldBio®, Missouri) at OD600 of 0.4-0.7 and grown until mid- to late-log phase (OD600 of 2.0 in
this work). Cells were harvested, washed, homogenized and prepared using the streamlined
method described previously (7,50).

2.2.2

Lyophilization of Extracts
Three extract types were lyophilized: 1) standard extract (xSTDlyo), 2) extract

supplemented with 0.05 gm per mL sucrose as a lyoprotectant (xSUClyo), and 3) a ready-to-use
mixture of extract and small molecules necessary for phosphoenolpyruvate-energized CFPS
([xSTD+ePEP]lyo). Lyophilization took place in 5 mL volumes as follows. Samples were loaded
into 70 mL cylindrical glass vials for shell freezing in a -40 oC ethanol bath (Just-A-Tilt Shell
Freezer Chiller SF-4Az, FTS Systems, New York) and incubated for a minimum of 5 minutes.
Vials were transferred to the freeze dryer (Flexi-dry MP, FTS Systems, New York) for 20 minute
periods. The operating conditions of the freeze dryer were -60°C and <120 mTorr, with a 19-20
o

C ambient temperature. At the end of each 20 minute drying period, vials were placed in the -

40oC shell freezer for 1 minute and subsequently replaced onto the freeze dryer. Lyophilization
11

continued in this manner until at least 95% of the estimated water mass was lost (typically 3
cycles), at which time the vials were chilled on shell freezer for 1 minute, then placed back on the
freeze dryer for an additional 60 minutes to provide for removal of the more tightly interacting
water molecules. Lyophilized product was gently ground using a chemical spatula in a glass vial,
aliquoted by mass, and stored in sealed microcentrifuge tubes.

2.2.3

Energy Systems
An aqueous phosphoenolpyruvate-based energy system (ePEPaqu) was employed as the

primary aqueous energy source for CFPS reactions, as previously described (15). The powdered
versions of the ePEPaqu energy system (ePEPpow) and a Glucose-based energy system (eGLUpow)
were used with slightly adapted reagent amounts indicated below (13). ePEPpow contained 0.137gm
of phosphoenolpyruvate (PEP), 0.0328gm of ammonium glutamate, 0.711gm of potassium
glutamate, 0.0099 gm of potassium oxalate, 0.0044gm of NAD, 0.0041gm of CoA, 0.0136gm of
ATP, 0.0091gm of CTP, 0.090gm of GTP, 0.0095gm of UMP, 0.0034gm folinic acid, and
0.0017gm of tRNA. eGLUpow contained 0.1081gm of glucose, 0.0328gm of ammonium glutamate,
0.5284gm of potassium glutamate, 0.0348gm of dibasic potassium phosphate, 0.0044gm of NAD,
0.0040gm of CoA, 0.0094gm of AMP, 0.0063gm of CMP, 0.0070gm of GMP, 0.0063gm of UMP,
0.0007gm of folinic acid, and 0.001706gm of tRNA. A separate solution of amino acids and a
separate solution of spermidine and putrescine were prepared. The spermidine and putrescine were
kept separate due to their extremely hydrophilic nature. Once all components –excluding amino
acid mix and spermidine/putrescine mix - were weighed out, they were combined in a 15mL
conical tube and mixed until homogeneous. The powder energy mixes were divided into carefully
weighed aliquots ranging from 0.04 to 0.06 g. When suspended in water for CFPS reactions, 4.157
and 5.377 mL water per gram powder were added to the PEP and glucose energy sources,
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respectively. The hydration volumes (mL water per gram energy powder) were evaluated such that
the final density of powdered components in hydrated powder systems equaled the density of
components in prepared aqueous systems (Appendix A Equation 9-4).

2.2.4

Rehydrating Extracts and Cell-Free Protein Synthesis.
DC™ assays (Bio-Rad, Hercules, California) were performed on samples of untreated

aqueous extract and rehydrated extract following the manufacturer’s specifications with Bovine
Serum Albumin as the control protein. Lyophilized extract was rehydrated in water according to
optimal ratio determined in DC™ assay (Appendix A).
Cell-free protein synthesis reactions were performed on each extract type as previously
described (20). In brief, reactions contained 25% v/v extract, 25% v/v energy source, 12 nM
plasmid encoding the GFP reporter protein (pY71-sfGFP), and optimized magnesium glutamate
concentration (in this study: 9 mM). Reagents were combined in microcentrifuge tubes and
pipetted into a 96-well flat-bottom opaque plate in 20 µL aliquots as droplets in the center of each
well. After the wells were sealed, the plate were incubated for 3 hours at 37 oC. Following the
reaction, 45 µL water was added to each well to dilute the reaction over the bottom surface of the
well. Resulting GFP fluorescence was measured using a Synergy Mx (BioTek Instruments, Inc.,
Vermont) and protein yield was determined using a linearly correlated calibration curve, as
previously detailed (49).

2.2.5

Bacterial Contamination
To consider potential bacterial contamination of the extracts, liquid extracts or lyophilized

extracts rehydrated with sterile ultrapure water were diluted in sterile SOC media and plated on
LB Agar Miller plates. Plates were incubated for 24 hours, at which point colonies were counted.
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2.3

Results and Discussion
Cell-free protein synthesis (CFPS) affords many benefits over in vivo synthesis systems

such as open access to the synthesis environment, rapid expression of recombinant PCR-products,
and easy application of in vitro synthetic biology. An additional beneficial trait of CFPS is that
cell extracts can be produced in large batches and stockpiled for future use (18). However, the
extract is traditionally stored at -80oC to maintain viability, increasing the storage expense and
complicating transport of the extract. Here we demonstrate that straightforward lyophilization of
E. coli-based CFPS extracts 1) significantly reduces storage volume, 2) stabilizes the extract at
less than ideal storage temperatures, and 3) decreases bacterial contamination. We also propose
and demonstrate that powdered energy systems may be utilized to create a CFPS system that can
be stored at high density and easily transported.

2.3.1

Extract Lyophilization, Rehydration, and CFPS
E. coli cell extracts (Table 2-1) were prepared as reported previously prior to lyophilization

(49). Two lyophilized extracts types were prepared: 1) standard extract (xSTDlyo) and 2) standard
extract with sucrose as a potential lyoprotectant (xSUClyo). By measuring the mass of the
lyophilized powered, the total mass loss was measured and percentage water loss approximated
based on DC™ assay analysis (Appendix A Equation 9-2), as seen in Figure 2-1A and B,
respectively. In all cases, extracts lost more than 97% of their estimated original liquid content.
The removal of the majority of liquid content reduced the storage volume over 2 fold and storage
mass over 9 fold.
Lyophilized extracts were ground into powders to promote homogeneity, then aliquoted by
mass for storage at -80, -20, 4 and 27 oC. Each lyophilized extract had a unique consistency.
xSTDlyo had the consistency of well-milled wheat flour and was easily ground into a fine
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homogenous powder. The fine powder was easily compressed, allowing for 2-3 times the storage
density of liquid extract. xSUClyo formed sticky heterogeneous granules, making it somewhat
difficult to achieve homogeneity and compressed storage.
Table 2-1 – Extracts and Energy Systems

In preparation for cell-free reactions, extract powders were suspended in sterile ultrapure
water. To establish a baseline for rehydration, xSTDlyo was rehydrated at multiple levels and
subjected to DC™ assay to approximate what volume-to-mass ratio would provide the equivalent
protein density as xSTDaqu (Appendix A Equation 9-1). From this baseline, the rehydration
volume:mass ratio was established for xSTDlyo and calculated for xSUClyo (Appendix A Equation
9-3).
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Figure 2-1 – Total Mass and Estimated Water Content during Lyophilization. (A) The total mass of the extract
was monitored throughout the lyophilization process. Extracts lost nearly 80% of their total mass in the first
40 minutes of lyophilization. (B) The water content remaining during lyophilization was estimated based on
calculated partial densities of water in the extract solution (Appendix A). In all cases, the remaining estimated
water content at the end of lyophilization was less than 2%. Error bars represent one standard deviation. n=3
for xSTDlyo, n=2 for [xSTD+ePEP]lyo, and n=1 for xSUClyo.

Extracts were tested for protein-synthesis viability over extended storage times with the
results displayed in Figure 2-2. Notably, xSTDaqu performed equally well at -80 and -20oC over
the span of 90 days, suggesting that -80oC storage may not be required for long term storage and
viability of CFPS extracts. Indeed, even at 4oC, xSTDaqu maintained effectively all of its activity
through 30 days. Under the storage conditions of 27oC, xSTDaqu exhibited exponential decay in
synthesis performance with less than 2% activity by day 30 and effectively no activity by day 60.
xSTDlyo and xSUClyo initially maintained an average 85% of the protein synthesis viability
of xSTDaqu. Extract viability was retained when stored at -80oC, while increasing storage
temperatures corresponded to increasing extract degradation rates. Notably, xSTDlyo and xSUClyo
stored at room temperature maintained about 20% protein synthesis viability at day 90. In contrast,
xSTDaqu stored at room temperature retained less than 2% viability by day 30. In short, the
lyophilized extracts retained significantly higher protein synthesis viability than the liquid extracts
when stored for more than 30 days above freezing.
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The addition of sucrose as a lyoprotectant to extracts prior to lyophilization did not appear
to be beneficial (Figure 2-2). Sucrose and other protein lyoprotectants theoretically stabilize
proteins from becoming denatured during the drying and rehydration process (51). However,
lyoprotectants are typically utilized to protect purified proteins in solutions that contain one or few
different types of proteins. In the case of extracts, the complex mixture of proteins and other small
molecules in solution may contain components that fill the role of stabilizing proteins during
drying, making the addition of sucrose unnecessary.

Figure 2-2 – CFPS Yields from Aqueous and Lyophilized Extracts Stored at Various Temperatures. Standard
storage for extracts is in an ultralow freezer at -80oC. Here, extracts were stored at -80oC, -20 oC, 4 oC, and
room temperature (27 oC±3 oC). The first data point (day 1) correspond to one day after lyophilization. Error
bars represent one standard deviation of protein yield and error contributed to rehydrating the extracts. n=3.
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To identify potential causes of lost extract viability at higher storage temperatures, we
examined bacterial contamination. Lysis efficiency using a high-pressure homogenizer such as
that used for this work has been reported to be 99.9996% (49). Prior to lysis, cell concentrations
are approximately 600 billion per mL, thus even at 99.9996% prepared extracts can have upwards
of 2.4 million cells per mL extract. Bacterial contamination was measured in colonies per µL
extract plated (Appendix A Figure 9-2). Regardless of storage conditions, xSTDaqu had the highest
amount of contamination, with an effective cell lysis efficiency of 99.99998% for xSTDaqu stored
at -80oC. By 14 days, xSTDaqu stored at room temperature was too contaminated to quantify
accurately and total CFPS viability dropped significantly, suggesting that bacterial growth likely
played a role in degrading the extract. In contrast, xSTDlyo showed zero colonies after 30 days at
room temperature and retained CFPS viability (Supplement Information Figure 9-2).

2.3.2 Powdered Energy Systems
Straightforward lyophilization of extracts lays the foundation for high-density and longterm storage of CFPS systems. However, extracts must be provided with an energy source and
essential building blocks to successfully transcribe mRNA and translate protein. Typically, energy
sources for CFPS are stored as solutions at -80oC due to the temperature sensitive nature of highenergy components such as nucleoside triphosphates, nicotinamide adenine dinucleotide,
coenzyme A, and phosphoenolpyruvate (PEP). In powdered formats, high density mixtures of
energy-rich components are less likely to suffer degradation. We therefore considered powdered
energy systems as a possible alternative to aqueous storage.
PEP-based energy systems are some of the highest yielding CFPS energy systems (14,52).
We therefore developed two PEP-based powdered energy systems: 1) a mix of extract and a PEPbased energy system subsequently lyophilized into powder ([xSTD+ePEP]lyo) and 2) a powder mix
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of individual components for a PEP-based energy system (ePEPpow) (Table 2-1) (14). To produce
[xSTD+ePEP]lyo, an 1-to-1 aqueous solution of xSTDaqu to ePEPaqu was lyophilized as described
above. The resulting powder exhibited a sticky heterogeneity similar to xSUClyo. [xSTD+ePEP]lyo
was maintained at -80 or -20 oC to mitigate extract degradation effects caused by higher
temperature storage, as seen in eSTDlyo and eSUClyo. ePEPpow was stored across all temperatures
to check against temperature sensitive degradation specific to the energy system.
The temperature sensitive nature of many ePEPpow components compelled us to propose a
more stable powdered energy system. We consulted the previously reported alternative energy
systems consisting of components less sensitive to temperature (7,13,15,53) (Appendix A). A
powdered glucose-based system (eGLUpow) was selected based on the stability of its components
to compare with powdered ePEPpow. Glucose is significantly cheaper than PEP and glucose-based
energy systems have been reported to reduce protein yield expenses compared to PEP-based
systems (USD per mg protein) (7). Also, glucose is quite stable in crystal form. To further increase
the stability of the glucose-based system, nucleotide triphosphates were replaced with their
monophosphate counterparts.
Rehydrating the powdered energy systems in small volumes added a challenge of obtaining
a proper pH. The PEP contained in ePEPpow has a low pKa, yet remains primarily insoluble below
pH 6. For [xSTD+ePEP]lyo, pH is addressed prior to lyophilization and the appropriate pH and
buffer ingredients are adjusted prior to lyophilization. However, ePEPpow pH must be considered
at the time of hydration. To address this concern, NaOH was added to the hydration mix at an
optimized level (Appendix A Figure 9-3).
CFPS using the powdered energy systems initially produced high protein yields, as seen in
Figure 2-3. Indeed, pH-optimized ePEPpow outperformed aqueous ePEPaqu. Comparisons of these
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two systems’ reveal that pH-optimized ePEPpow has a lower pH than ePEPaqu, suggesting that the
ePEPaqu system would benefit from pH-optimization (Appendix A Figure 9-4). Initial yields from
eGLUpow were very low, totaling less than 5% of the ePEPaqu, which was not unexpected based on
previous work and the longer pathway required to properly metabolize glucose (7).
Over the 60 day storage time, ePEPaqu performed surprising well at elevated storage
temperatures, maintaining over 25% viability at room temperatures (Figure 2-3). This result was
unexpected due to the purported instability of its components. eGLUpow yields remained low
throughout storage, but remained relatively consistent with no observable loss in yields, suggesting
it is quite stable. However, the low yields produced with eGLUpow severely limit the utility of such
a CFPS system.
The powdered PEP-based energy systems ([xSTD+ePEP]lyo and ePEPpow) maintained a
minimum of 35% of the viability of the ePEPaqu over 60 days. Although [xSTD+ePEP]lyo displayed
upwards of 95% viability compared to xSTDaqu with ePEPaqu, the lyophilized system exhibited
significant inconsistencies in performance. Inconsistent performance of [xSTD+ePEP]lyo is likely
due to the difficulty to homogenize the sticky lyophilized powder. ePEPpow with optimized pH
performed well overtime at all storage conditions. Indeed, at 60 days, ePEPpow stored at room
temperature retained over 33% of its original viability, over 30% more than ePEPaqu.

2.4

Conclusion
The straightforward methods of extract lyophilization and powdered energy systems

presented here allow for >2x reduction in storage volume and >10x reduction in storage mass of
eCFPS systems. These powdered systems are also more stable than their aqueous counterparts,
permitting 1) more economic storage, 2) simplified transport conditions, and 3) a simplified “justadd-water” protein synthesis system. These benefits make powdered CFPS systems compelling
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candidates for promising applications such as pharmacy-on-a-chip microfluidic devices for rapid
“on-the-site” treatment and rapid large-scale vaccine or therapeutic protein production from stockpiled extract. Indeed, the development of lyophilized extract and powdered energy systems for
CFPS reduces the cost, simplifies the procedure, and expands the viable applications of CFPS
technology.

Figure 2-3 – CFPS Yields from Aqueous and Powdered Energy Systems Stored at Various Temperatures.
Standard storage for CFPS energy sources is in an ultralow freezer at -80oC. Here, systems were stored at 80oC, -20 oC, 4 oC, and room temperature (27 oC±3 oC). The first data point (day 1) corresponds to one day after
lyophilization or mixing of the powder. Error bars represent one standard deviation of protein yields and error
contributed to hydrating the powders. n=3.
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3

ALTERNATIVE FERMENTATION CONDITIONS FOR EXTRACT
PREPARATION

This chapter is an adaptation from the article entitled “Alternative Fermentation Conditions
for Improved Escherichia coli-based Cell-free Protein Synthesis for Proteins Requiring
Supplemental Components for Proper Synthesis” published in Process Biochemistry in February
2014. This work was developed and lead by myself with the help of Anna Hawes, Prashanta
Shrestha, Jay Rainsdon and Jeffrey Wu.

3.1

Introduction
The in vitro protein production system known as Cell-free Protein Synthesis (CFPS) is a

propitious system for protein production when direct access to the reaction environment is desired
(6,35). Compared to in vivo expression, CFPS maintains many advantages such as improved
monitoring and control, reduced reaction volumes, virtually silenced background expression,
simplified purification, and removed effect of many toxins (33,35,54,55). These traits make it quite
versatile for applications in protein engineering such as the development of pharmaceutical
proteins (18), toxic proteins (19,32), vaccines (56,57), bioimaging techniques (58), proteomic
studies (59) and high-throughput protein engineering (6,12,60). In addition, cell-free systems are
increasingly being exploited for the direct combination of biomachinery from different organisms
to create synthetic pathways and products which has resulted in the emergence of cell-free
synthetic biology (33,34,55,61-64).
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One prevalent, straightforward, and enduring cell-free system is based on crude extracts
prepared from Escherichia coli (E. coli) (35,65). Over the last 50 years, E. coli-based CFPS
(eCFPS) methods have been modified to reduce cost and labor (10,21,66,67), decrease background
gene expression (21,68), and increase protein production to levels to exceed 1 mg/mL (61,68,69).
While these adjustments have made eCFPS more widely accessible, economic, high-yielding, and
applicable than many other CFPS systems, the range of proteins that can be correctly produced is
restricted by the inherent limitations of its prokaryotic-based biomachinery (35). For example,
unmodified eCFPS cannot produce active [FeFe]-hydrogenases, cannot correctly fold some
complex eukaryotic proteins, and cannot incorporate noncanonical amino acids site-specifically.
However, the scenarios mentioned can be and have been accomplished in eCFPS through synthetic
pathways by adding necessary purified exogenous components to the in vitro reaction and/or by
heterologous expression of the necessary components during the E. coli fermentation used to
prepare the extract eCFPS (2,8,60,70). Systems based on purified machinery become more labor
intensive and monetarily expensive with each additional component, as epitomized by the P.U.R.E
system where every component is purified and then reconstituted for eCFPS (43), making it greater
than 100 times more expensive than crude extract systems (49). To counter the expense of such
purification and increase the accessibility and efficacy of eCFPS systems requiring supplemental
components, here we report the effects of plasmid-based heterologous gene expression on cell
fermentation and cell extract viability, and demonstrate optimal conditions for such systems.
Specifically, we optimized the fermentation conditions for cells heterologously expressing
supplemental components in efforts to increase functional protein yields and broaden the potential
of protein engineering and synthetic biology applications with eCFPS systems.
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The gene expression profile of bacteria changes according to the growth rate and phase of
the cell (71,72). Standard eCFPS traditionally harvests cells during the mid- to late-log phase to
achieve maximum protein yields (25,68). The basis of this tenet is part empirical and part logical.
Cells growing the most rapidly contain an efficient balance of transcription/translation machinery
to maintain the steady pace of cellular division (71). In our experience, the heuristic of harvesting
during mid- to late-log phase is highly accurate when standard, simple and stable proteins are being
produced. To our knowledge, there have been no other reports exploring harvesting cells for
eCFPS extracts outside of the mid- to late-log phase. However, Seo, Bailey and others
demonstrated that maximum growth rates seen during log phase correspond to minimum plasmid
copy number in vivo (72,73). Others have demonstrated the positive correlation between plasmid
copy number and expression of plasmid-borne genes (74-76). Based on these findings, we
hypothesized that a delayed harvest time following the log phase would yield higher levels of
supplemental components and achieve more favorable ratios of endogenous to supplemental
machinery. To test the effects of harvest time on extract viability of eCFPS, we explored three
distinct cases: 1) the standard case of E. coli without plasmids as a control, 2) the modified case
of E. coli containing a plasmid with genes for protein-folding chaperone complex GroEL/GroES
(GroE), and 3) the modified case of E. coli containing plasmid with tRNA/tRNA-synthetase (RS)
pair capable of incorporating a noncanonical amino acid at the amber codon (UAG) using a cellfree synthetic biological pathway (Figure 3-1).
The modifications described in this report are applied to two distinct eCFPS cases that
demonstrate a conserved optimum harvest condition, suggesting that similar conditions could
benefit other eCFPS systems using heterologous expression of essential supplemental components.
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These techniques enhance the feasibility for using eCFPS as a high-throughput, economical, and
efficient protein engineering and synthetic biology tool.

Figure 3-1 – Standard and Modified eCFPS Systems Employed for Exogenous Element Analysis

3.2

3.2.1

Materials and Methods

E. coli Cell Extract Growths
All extracts were prepared using the Escherichia coli strain BL21Star™ DE3 (Invitrogen,

Carlsbad, CA) as follows: 1) containing no plasmid (NP), 2) containing pEVOL-pPrF plasmid
(pEVOL), and 3) containing pOFX-GroEL/ES plasmid (pOFX). The pEVOL-pPrF plasmid, a
kind gift from Dr. Peter Schultz (Scripps Research Institute), expresses chloramphenicol antibiotic
resistance protein as well as a Methanocaldococcus jannaschii tyrosyl-aminoacyl-tRNA
synthetase/tRNA pair (77). The pOFX-GroEL/ES plasmid, a kind gift from Dr. Dong-Myung Kim
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(Chungnam National University), expresses spectinomycin antibiotic resistance protein as well as
the chaperone proteins GroEL and GroES (2).
Each extract was grown with appropriate antibiotic and using sterile technique. All tubes
and flasks were incubated at 37 oC and 280 RPM. Overnight cultures in 5mL LB media were
inoculated into 100mL 2xYT media in baffled intermediate flasks and grown until an OD600 of 2.
Approximately 90 mL from the intermediate flasks were inoculated into 1L volumes of 2xYT
media in 2.5L shake flasks. For cells grown with MOPS buffer, the 2.5L shake flasks contained
1L of 0.1 M MOPS in 2xYT media. At a cell density between OD600 0.5 and 0.7 in the flasks, all
fermentations were induced with 1mM isopropyl-β-d-thiogalactopyranoside and the pEVOLharboring fermentations were additionally induced with 0.22g L-arabinose per liter fermentation.
At 3, 4.5 and 6 hours after induction 300mL of extract were harvested. Two replicates were
performed for each extract condition. Harvested cells were pelleted, homogenized using an
Avestin Emulsiflex-B15 Homogenizer, and prepared as previously reported (49).

3.2.2

Cell-free Protein Synthesis Reactions
Cell-free protein synthesis reactions were performed with the following plasmids: 1) pY71-

sfGFP 2) pY71-sfGFPT216Amber (8) and 3) pk7-CalB, a generous gift from Dong-Myung Kim
(2). Reactions were run as previously described (20) with the following modifications. Reactions
of 15 μL were conducted in flat bottom 96-well plates covered with plate sealing covers. Reactions
were performed at 30 oC and 37 oC for 3 and 8 hours. Four replicates of each reaction were
performed. As specified in the Results and Discussion, some reactions with the pY71sfGFPT216Amber had purified Methanocaldococcus jannaschii aminoacyl-tRNA synthetase
added at 12 µg per mL, as previously described (20). All reactions with the pk7-CalB plasmid
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contained a 4:1 molar ratio of oxidized:reduced glutathione to stimulate disulfide bond formation
(2,78).

3.2.3

Protein Yield Assays
GFP standard curve was assessed by comparing radioactivity and fluorescence yields, as

previously described (49). Protein yields for CalB were measured by adding C14-Leucine to the
eCFPS reactions and scintillation counting the TCA-precipitated reaction product, as reported
previously (79).

3.3

Results and Discussion
The traditional approach to eCFPS relies on using extract prepared from cells harvested at

mid- to late-log phase (68). However, when extracts are prepared from cells grown with plasmids
heterologously expressing supplemental components to aid in the synthesis of properly produced
proteins, harvesting at mid- to late- log phase may not achieve an optimal balance of native and
supplemental machinery to enable efficacious production of fully functional protein. To identify
potentially more favorable conditions for cell fermentations used to produce extracts for eCFPS
reactions, the following parameters were explored: 1) delayed harvest times (3, 4.5, or 6 hours post
induction) and 2) buffered growth media with or without MOPS. MOPS was added to adjust
against pH deviations typically observed during extended cell growth.
Under these growth parameters, we examined a standard eCFPS system with extract from
cells containing no plasmid (NP) and two nonstandard plasmid-bearing systems: 1) extract from
cells harboring the plasmid pOFX-GroEL/ES (pOFX), and 2) extract from cells harboring the
plasmid pEVOL-pPrF (pEVOL). The NP system is defined as the standard eCFPS that uses extract
from BL21Star™ DE3 E. coli cells without additional plasmids to and is commonly used to
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produce proteins that do not require additional machinery or synthetic pathways. The pOFX
system uses extracts from BL21Star™ DE3 E. coli cells harboring the pOFX plasmid and thus
includes the folding chaperone proteins GroEL and GroES. The pEVOL system uses extracts from
BL21Star™ DE3 E. coli cells harboring the pEVOL plasmid such that it includes an E. coliorthogonal tRNA/tRNA synthetase (RS) pair. Thus the pEVOL system allows for the
incorporation of a noncanonical amino acid when the amber stop codon is successfully suppressed.
This tRNA/RS pair is essential for full length translation in proteins containing internal amber
codons.
To test these cases, we expressed green fluorescent protein (GFP), Candida antarctica
Lipase B (CalB), and a mutant GFP (pPaGFP). The protein GFP requires only native machinery
for expression and therefore was chosen as a control across all cases. CalB is a large and complex
eukaryotic protein that is only produced at low soluble yields without the aid of folding chaperones
(2,12). Therefore, CalB was expressed in the pOFX system as well as the standard system. pPaGFP
contains a T216 to amber codon mutation that requires the foreign transcription machinery found
on pEVOL to produce full-length pPaGFP and therefore was only expressed with the pEVOL
system (8).

3.3.1

Growth Conditions and Outcomes
Cells used to prepare eCFPS extract fermented in 1L cultures using the simple and

inexpensive baffled shake flasks, as previously reported (10,49,67). This simple preparation
technique allows for the eCFPS technology to be readily adapted by labs without specialized
fermenters and may be combined with simple cost-effective lysis technologies, effectively
lowering the entrance cost of the technology further (49).
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As shown in Figure 3-2A, NP fermentations exhibited a definitive log phase with a
transition near or shortly after 2 hours post induction to a clear stationary phase. Although MOPS
clearly buffered the growth media, no apparent or statistical difference appeared between the
growth profiles of buffered or unbuffered NP. Cells harboring plasmids displayed a similar log
phase to the NP growths and began to transition out of log phase near or shortly after 2 hours post
induction. However, the transitioning period between log and stationary phase took ~6 times
longer for plasmid-harboring cells, resulting in higher overall OD600 and growth rate at harvest
compared to the NP growths (Figure 3-2A). These results are consistent with previous reports that
growth rates and maximum densities of cells harboring plasmids are altered by the presence of the
plasmids (72,80).
The addition of the plasmid expressing heterologous elements during cell growth has the
potential to increase the overall metabolic load and in turn change the proteomic profile of the cell
(Appendix B Figure 10-4) (81). These effects could be exaggerated by factors such as plasmid
copy number, gene expression level, and gene function (80,81). Both plasmids employed (pOFX
and pEVOL) are high-copy number plasmids and should express the promoted genes at a high
level The consistent deviation of the pOFX and pEVOL fermentation profiles from the plasmidfree cells suggests that similar fermentations will also likely result in altered growth profiles
As expected, the pH of media for cells grown with MOPS fluctuated less. Furthermore, all
unbuffered growths exhibited a similar pH trend and all buffered growths exhibited a similar trend
(Figure 3-2B). However, the pOFX growth trends were shifted approximately one half pH unit
lower than the NP and pEVOL growths. The lower pH profile of pOFX growth is attributed to the
mechanism of spectinomycin antibiotic resistance, which results in the release of pyrophosphoric
acids (82).
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Figure 3-2 – Cell Growth and Media pH Curves for BL21Star™DE3 with and without Harboring Plasmids.
Data was collected beginning at time of induction (0.5<OD600<0.7). Growths were performed with and without
0.1M MOPS Buffer. (1A) OD600 profile of the fermentations. (1B) pH profile of the fermentations. The results
from 2 separate fermentations (n=2) were averaged for each data point. Error bars represent one standard
deviation.

To analyze the impact of growth conditions and harvest time on extract protein profiles,
SDS PAGE and densitometry were performed on pEVOL and pOFX extracts (Appendix B Figure
10-4). The heterologous synthetase and GroEL/ES were overexpressed in pEVOL and pOFX,
respectively. The amount of supplemental components as well as other extract proteins exhibited
extract to extract variation and do not appear clearly correlated with harvest time. The changes
throughout the extract profiles indicated that supplemental component concentration was not a
singly important trait and the overall balance of the endogenous and supplemental components in
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the extract likely plays a more significant role in extract viability. This is not entirely surprising,
considering the many enzymes and small molecules involved in protein synthesis.

3.3.2

eCFPS Yields
After growth, cells were prepared for eCFPS reactions by harvesting, lysis, and

clarification as reported previously (49). Cell extracts were then used with eCFPS to express the
test proteins under the following traditionally optional conditions: 1) eCFPS reaction time (3 or 8
hours) and 2) eCFPS reaction temperature (30 or 37 oC) with n= 4 replicates (n= 2 extract
preparations, n=2 eCFPS reactions per extract). To simplify the analysis of parameter impact on
yields and cross-case comparisons, yields were fit to a simple linear regression, described in Figure
3-3. Individual reaction results can be found in Supplement Information (Figure 10-1).

3.3.3 Harvest Time
The NP system for eCFPS expressing GFP behaved consistent with the expectation that
mid- to late-log phase harvesting produces highest yields, with highest yields occurring while
using extract harvested nearest the log phase. For GFP, the average yield decreased by
approximately 43%-45% for each 1.5 hours delay in harvest. The NP case expressing CalB also
produced highest yields (total and soluble) when harvested at 3 hours and, as expected, the average
solubility of CalB expressed with NP was low, at approximately 30%.
Although GFP does not require supplemental components, GFP expressed in pOFX and
pEVOL extracts yielded 15-30% more protein than the standard NP case and appeared unaffected
by harvest time (Figure 3-3). A possible explanation for the increase in yields is that cells harboring
plasmids exhibited a delayed onset of stationary phase during cell growths, likely resulting in a
distinct proteomic profile in comparison to the NP case. The lack of impact of harvest time on GFP
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in pOFX and pEVOL extracts may be due to the similar growth rates observed across all harvest
times.

Figure 3-3 – Normalized Impact of Individual Parameter on CFPS Yield. A simple linear regression (Equation
A) considering only parameter extremes allows for facile analysis of a given parameter’s impact on specific
extract/protein combinations. Parameter coefficients (βi) were normalized within their regression, as described
in Equation B. Normalized parameter coefficients (°βi) are plotted to readily compare relative impact within
and between extract/protein conditions. For example, GFP yields expressed in NP extract are heavily affected
by harvest time, with this statistically significant parameter coefficient accounting for roughly 55% of the
regression weight and favoring a 3hr harvest time point. In contrast, the normalized harvest time parameter
coefficients (°β0) for GFP yields produced in pEVOL or pOFX have no statistical significance to their
respective linear regressions. The individual yields for each case are available in Figure 10-1 (Appendix B).
Parameters were simplified to high/low as follows: xHarvestTime [3hr = -1; 6hr = 1], xMOPS [No = -1; Yes = 1],
xCFPSTime [3hr = -1; 8hr = 1], and xCFPSTemp [30 oC = -1; 37 oC = 1]. Error bars represent 95% confidence interval
for the regression coefficient. *Designates the null hypothesis p-value of regression coefficient is <0.05. The
individual yields for each case are available in Figure 10-1 (Appendix B).

For pOFX extract expressing CalB, longer harvest times results in higher total and soluble
CalB yields (Figure 3-3). These yields were upwards of 3 times higher than previously reported
CalB yields with similar CFPS systems (2,12). CalB expressed in pOFX extract was more than
twice as soluble as CalB in NP (Appendix B Figure 10-2). The increase of CalB solubility was
expected, as the addition of the GroE chaperone complex should aid in the proper folding of the
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protein after translation (2,12). Curiously, CalB total yield was also more than twice as large in
pOFX as NP. The increase in total yields is likely due to the overall increase of yields in pOFX
compared to NP. This could also be attributed in part to a reduction of insoluble CalB, since
aggregation of CalB may lead to coprecipitation of essential transcription and translation
machinery. For reference, a selection of CFPS-produced CalB samples were assayed for lipase
activity and achieved an average activity of 70% of a commercially acquired CalB standard
(Appendix B Figure 10-3).
The pEVOL case expressing pPaGFP (GFP modified for noncanonical amino acid pPa
incorporation) performed consistently better with delayed harvest time (Figure 3-3). The fulllength pPaGFP production yields with the PEVOL extract were originally very low (less than 4%
of the standard GFP yields), causing us to hypothesize there may not be sufficient foreign tRNAsynthetase or tRNA. Indeed while we performed this work, Albayrak and Swartz reported that the
synthetase is likely the primary limiting factor in this relationship (52). We therefore performed
reactions with exogenously purified tRNA-synthetase supplementing the pEVOL extract
(pEVOL+RS, Figure 3-3). The ensuing yields increased by over 300%, confirming that the
synthetase had been limiting (Appendix B Figure 10-1). Despite the limitation of plasmidexpressed synthetase, there remained a significant positive trend in yields with regards to delayed
harvest times, suggesting that more plasmid-expressed tRNA may be available at later harvest
times, resulting in an overall average increase in yields of greater than 150% by harvesting the
pEVOL extract well after log phase (Appendix B Figure 10-1).
Delaying harvest was universally beneficial for pEVOL extracts and improved the efficacy
of pOFX extracts, as well. The strong benefit in pEVOL is likely due to the essential nature of the
transcription machinery expressed in that system. In essence, the pEVOL machinery must compete
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with endogenous release factor 1 for the amber stop codon and is therefore more heavily affected
by concentration. Thus, a delayed harvest is particularly important when there is competition
between the exogenous and endogenous machinery.

3.3.4

pH Buffer
Extracts from cells fermented in MOPS-buffered media typically performed equally as well

or better than their unbuffered counterparts. Buffering the media during growth likely decreases
the burden on cellular mechanisms that adjust against suboptimal pH environments and thus may
protect against shifts in the proteome that could be deleterious to extract viability (83). An
exception from this general trend was the expression of soluble CalB in pOFX extracts where
MOPS buffering was generally detrimental to yields. The exception is not all together surprising
due to the pH-reducing effect of the antibiotic resistance mechanism used by the pOFX plasmid.
Indeed, this effect can be observed in Figure 3-2B, where at harvest times of 3, 4.5, and 6hrs the
pH of the unbuffered pOFX fermentation was closer to the MOPS-buffered NP and pEVOL
fermentations than the unbuffered NP and pEVOL fermentations.
Closer inspection of the pH profiles and the respective yields suggests that maintaining the
extracellular pH in the range 7.2-7.5 is preferred for viability of supplemented extracts. High or
low deviations from this range appear to be deleterious to extract viability. This relationship is
expected, as previous reports show that E. coli is sensitive to pH, particularly during active cellular
reproduction (83,84).
Augmenting the growth media with MOPs adds a further cost to the extract preparation
and raises the concern that addition of this chemical reduces the economy of the eCFPS. Yield
improvements due to buffering more than offset the cost of the buffering agent in half of the
reactions, with an average decrease in cost of 52% (data not shown) (49). The reactions costs not
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offset by yield improvements increased the average cost of reaction by 14%. The cases with
decreased reaction costs generally corresponded to the cases benefitting from MOPs buffering, as
seen in Figure 3-3.

3.3.5

eCFPS Time and Temperature
Universally, all proteins expressed in eCFPS reactions for 8 hours outperformed 3 hour

reactions, with the exception of GFP in NP and soluble CalB yields. Generally, longer reaction
time should allow for higher overall conversion. The inconsequential effect of reaction time on
GFP in NP may imply that the majority of the protein is synthesized within the first three hours
and that most of the energy is exhausted, as has been previously reported (66). Previous works
have also reported similar asymptotic maximums in protein yield between 3-8 hours (8).
The reduced solubility of CalB in 8 hour reactions compared to 3 hour reactions indicates
increased aggregation of CalB. The complexity, disulfide bonds, and overall bulk of CalB likely
contribute to higher aggregation rates than production rate. As expected, the presence of GroE
chaperones reduces the negative impact of longer reaction time on solubility.
Universally, all extracts performed equally well or better at 30 oC than 37 oC. Although 37
o

C is a traditional eCFPS reaction temperature, our results are consistent with multiple previous

reports that advise performing reactions at 30 oC to achieve higher yields, particularly when
nonstandard components are employed (8,9).

3.4

Conclusion
Here we have considered alternative fermentation conditions for three fundamentally

different cases of eCFPS: 1) a standard extract - NP, 2) an extract supplemented with nonessential
components - pOFX, and 3) an extract supplement with essential components for successful
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translation – pEVOL. The traditional method of harvesting during or toward the end of log phase
was shown to be best for the NP case compared to harvesting at later time points. However, a clear
benefit to delayed harvesting of cells for extract preparation was observed when supplemental
components were plasmid-expressed during fermentation. In addition, buffering the fermentation
with MOPS was shown to be typically cost-reducing when beneficial to yields, although this effect
can be complicated by factors such as antibiotic resistance mechanisms that affect the pH. To
further reduce cost, other buffering agents might serve as possible inexpensive alternatives.
Overall, the conservation of positive benefit at delayed harvest time and the positive effects of
MOPS buffering intimates that the principles discussed here would apply to eCFPS systems
requiring other supplemental components and the emerging field of cell-free synthetic biology
(33,34,61). This potentially expands the range of proteins that could be produced in eCFPS and
enhances the potency of protein engineering and synthetic biology applications with eCFPS.
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4

RAPID VACCINE DEVELOPMENT AND PRODUCTION

4.1

Introduction
Vaccines have had a potent impact on the world. Due to vaccines, diseases such as

smallpox and polio have nearly been eradicated (85,86). Despite promising results, hundreds of
viral pathogens continue to persist throughout the world, having devastating impacts on the social,
political, and economical status of those affected. Foot-and-mouth disease (FMD) is one such virus
that persists throughout large swathes of the globe (87). There have been multiple vaccines
developed against FMD; however the genetic diversity of the virus serotypes and subtypes
prevents a single vaccine from being universally effective (88). In efforts to eradicate FMD, a
rapid, versatile, and economically feasible system must be developed. Using CFPS technologies,
we work towards a system that can rapidly produce diverse recombinant proteins for safe and
economical vaccine production.

4.1.1

FMD Virus and Related Challenges
Foot-and-mouth disease virus belongs to the family picornaviridae – small, non-

enveloped viruses with a single positive-sense RNA molecule. The viral genome encodes for 4
structural proteins (VP1, VP2, VP3, and VP4) and several non-structural proteins that promote
infection, replication, and proper assembly of the virus particle (87). These proteins are encoded
as a single polyprotein, then cleaved by a protease (protein 3C) located towards the C-terminus
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of the polyprotein. FMD is genetically diverse, with seven distinct serotypes: type O, A, C, SAT
1, SAT 2, SAT 3, and Asia 1 (89). Furthermore, subtypes within each serotype contain a large
spectrum of genetic diversity due to high mutation rates within the virus (90). The broad genetic
diversity between and within serotypes complicates identifying and protecting against disease
(91). Specifically, the variability in the epitope regions can reduce or effectively eliminate crosssubtype or -serotype protection from previous infection or vaccination as occurred in Iran in
2005 (88).

4.1.2

Disease Traits and Related Challenges
In addition to the significant genetic diversity of the virus, FMDV infects diverse hosts,

affecting over 70 species of wild and domestic cloven-hoofed species such as cattle, sheep and
swine (87). The variety of hosts and diversity of serotypes synergistically complicates disease
prevention. Furthermore, signs and disease severity may significantly differ from species to
species. Generally, cattle have obvious oral and pedal lesions, while swine primarily have pedal
lesions (92). Sheep show milder signs - 25% of infected sheep develop no lesions and a further
25% develop only one lesion - making visible diagnosis difficult or impossible (93). In addition a
number of other viral diseases including vesicular stomatitis, swine vesicular disease, and
vesicular exanthema of swine cause disease signs similar to FMD [2]. Incubation periods from
exposure to first signs vary by initial infection and route of transmission, ranging from as little as
1 day to up to 14 days (94). Therefore, some animals may remain asymptomatic and act as
carriers while others are misdiagnosed. Such cases increase the possibility of accidental
transmission from primary or secondary contact between herds.
The ability of the virus to infect cross-species through sundry routes increases
transmission opportunities, particularly where livestock agriculture is densely populated (95).
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Cattle and sheep are primarily infected through respiration of the virus in aerosol form, while
swine are more likely to be infected through ingestion or subcutaneous wounds (94). Shedding of
the virus may occur through multiple routes including in aerosol form, urine, feces, and bodily
fluids (96). Excreted virus can retain virulence for significant durations in aerosol form, with
examples of some strains naturally traveling as far as 300 km (94). The extent of FMD
transmission can be further amplified by incidental transport on vehicles, humans, water, and
animal products (94,97). The diverse routes of shedding and transmission coupled with the
diversity of host species provide myriad opportunities for spread of the disease.
In certain hosts, including cattle and buffalo, the virus can persist and these
asymptomatic, persistently infected animals can remain potentially contagious for up to 5 years
(91,98). Infected animals are thought to reach a maximum transmission potential within 12 days
of infection (99). In a dead host, the virus may remain stable, and persist in an infectious form
for as long as 11 days in muscle tissue, and 4 months in the liver (97). Also, many other animal
products such as milk and cheese can act as incubators of the virus (97). Some experts suspect
that the longevity of the virus in animal products is what led to the 2001 outbreak in the UK. The
outbreak is thought to have started when a farmer purportedly fed his animals FMDcontaminated imported food scraps, which were insufficiently heat treated to remove the
possibility of infection (100).
The complexities of this highly infectious and persistent disease complicate strategies of
eradication. Although an inactivated FMD-vaccine was developed and successfully used on large
numbers of animals in the 1950’s, FMD is still prolifically spread through the world (101,102).
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4.1.3

Predominant Vaccine Technology
The predominately utilized FMD vaccine is based on inactivated FMDV (103). This

vaccine is typically produced from live FMDV amplified in baby hamster kidney-21 cells,
chemically inactivated, partially purified by some manufacturer’s, and subsequently formulated
with an adjuvant (104). Throughout the process, a sterile environment and meticulous
management of temperature and pH is essential to ensure production of an effective,
noninfectious vaccine (105). This vaccine technology comes with the inherent risk of live virus
release from production facilities or insufficient inactivation of the virus during vaccine
preparation (104). Indeed, it is thought that the 2005 FMD outbreak in China initiated when
insufficiently inactivated virus was used to vaccinate, resulting in an outbreak that spread
throughout China and into Russia and Mongolia (88). In addition, the 2007 outbreak in the UK
was caused by inadvertent release of virus from the Pirbright vaccine and research institute (96).
The risk of virulent virus contamination or insufficient inactivation during vaccine
production requires that production facilities maintain rigorous biosafety standards. This restricts
the locations where production facilities can be successfully constructed, maintained, and
operated. Furthermore, these facilities must operate at a high level of containment. The distance
between production facilities and regions of FMD infections presents a logistical challenge of
distribution, particularly where international borders are concerned. To help alleviate this
challenge, in some parts of the world FMD vaccine banks have been established to increase
vaccine accessibility (106,107).
FMD vaccine banks decide how much vaccine they will store for any given serotype, and
regularly test these stored vaccines for efficacy (108,109). These tests are essential as a concern
with the current technology for inactivated virus vaccine production is the possible selection of
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antigenic variants during virus replication (110,111). It has been found that the selected variants
may not always be protective against the circulating parental virus strain. In addition, the choice
of which vaccines to store is complicated by limited cross-subtype and cross-serotype protection,
requiring individual vaccines against each subtype that is currently circulating for effective
protection (108,112). Vaccines must also be periodically replaced due to a shelf life of 1-2 years
for conventional FMD vaccines (91). Storage of vaccines as concentrated antigens in liquid
nitrogen improves shelf life (113). However, these concentrated antigens must be shipped to
manufacturers for formulation with an adjuvant when needed, thus delaying their use in the field.
Administration of the vaccine also presents its own set of complexities, such as proper
handling, correct dosage, and optimal time of vaccination. All of these variables can significantly
impact the efficacy of the vaccine (104,114). For example, higher doses of vaccines generally
result in better protection and reduce the time from administration to protection (104). As a
consequence, during outbreaks in previously disease-free countries, emergency vaccination of
animals with 6 protective dose 50 (PD50) is recommended by the OIE. Complexities of
administration make it desirable for trained persons to administer the vaccine. However, persons
administering vaccines to multiple herds may inadvertently act as disease carriers (115).
Furthermore, regions with inadequate veterinary services face the added challenge of increasing
competency among those administering vaccination (116).
Other vaccine technologies are becoming available that are attempting to address the
shortcomings of inactivated virus vaccines. These include empty capsid vaccines, DNA vaccines,
recombinant protein vaccines and peptide vaccines, among others (103,114,117-119). An
example of a novel vaccine technology is the recent development of a replication-defective
human adenovirus vector containing the FMDV capsid protein coding region for serotype A24
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Cruzeiro (120). This vaccine has been granted a conditional license by the Center for Veterinary
Biologics, Animal Plant and Health Inspection Service, USDA. This license allows the vaccine
to be included in the U.S. National Veterinary Vaccine Stockpile to be used in cattle in the event
of an emergency situation (121). Recent reviews have described the benefits and limitations of
this and other novel vaccine technologies (103,119,122).
Vaccine production technologies must also become more efficient and economical, as is
being pursued with emerging technologies involving production of virus-like particle FMD
vaccines produced in E. coli, in insect cells infected with recombinant baculoviruses, and in cellfree systems (1,19,87,104). To be successful for eradication, vaccine technologies and systems
must avoid the pitfalls of inactivated viruses and be sufficiently inexpensive as to be
economically viable for developing countries. Using CFPS technologies, we work towards a
rapid expression platform capable of production of diverse FMD proteins for safe and
economical vaccine production.

4.2

4.2.1

Materials and Methods

Gene Design
Genes were designed using Gene Designer (DNA2.0, Menlo Park, CA) based on the

GenBank Accession number AY593768.1. After selective removal of portions of the full protein
(described in Results and Discussion), the codons were optimized for expression in Escherichia
coli based on Class II Codon Usage. The resulting gene was cloned into the T7-expression vector
pJ411 and called pJ411-P1-3C. To express the 3C protein exclusively, the Lpro-P1-2A section of
the gene was excised and the vector was re-ligated, resulting in pJ411-3C.
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4.2.2

CFPS Expression and Coexpression
CFPS reactions were performed as described previously with the following modifications

(19). Coexpression from pJ411-P1-3C and pJ411-3C was performed at a consistent vector
concentration (12 nmol per L) with the following ratios of pJ411-P1-3C to pJ411-3C: 1:0, 5:1, 2:1,
1:1, 1:2, 1:5, and 0:1. Reaction volumes were scaled from 20 µL to 1 mL without significant
change in reaction performance.

4.2.3

Scintillation, SDS-PAGE and Autoradiography
Radiolabeled amino acids (Leu

14

C) were included into the CFPS reactions for

incorporation into the proteins. Protein expression levels were calculated by TCA precipitation
and liquid scintillation counting, as previously described (19). In cases of co-expression, protein
yields were calculated based on the most prevalent gene vector in the reaction or pJ411-P1-3C in
cases of equal vector concentrations.
To assess proper protein cleavage, the reactions were subjected to denaturing 10% Bis-Tris
SDS-PAGE with MOPS running buffer according to the manufacturer’s specifications (Novex
Life Technologies, Grand Island, NY). Gels were dried and exposed to autoradiographic film for
1 week. Films were subsequently developed and analyzed.

4.3

4.3.1

Results and Discussion

Innocuous Gene Design
One of the primary drawbacks to predominant FMD vaccine technology is the necessity to

have fully active and infectious particles at some given stage of vaccine development. The
presence of complete viruses carries with it the inherent risk of accidental release and outbreak.
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Recombinant expression technology (CFPS) allows us to circumvent the issue entirely by
designing a gene unable to self-replicate and lacking the elements for production in the host. The
steps to designing an effective yet innocuous gene are:
1. Exclude elements that aide in host expression
2. Exclude elements that aide in genome replication
3. Exclude elements that aide in host infection cycle
The first step in innocuous gene design is to identify the elements that promote protein
expression in the host. In this case, the 5`and 3` untranslated regions (UTRs) both play a role in
expression including an internal ribosome entry site (IRES) and a poly-A tail, respectively (87).
As depicted in Figure 4-1, we exclude these elements and replace them with the specific T7
promoter (5` UTR) and a non-poly-A region (3` UTR).

Figure 4-1 – Design of Innocuous FMD Gene

The second step in innocuous gene design is to remove the possibility of undesired genome
replication. In this case, the protein 3D is known to be a RNA-replicase for genome replication
during the infection cycle (87). We exclude the portion of the gene that encodes for 3D.
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The third step is to identify and exclude elements that aide in the host infection cycle and
are unnecessary for vaccine activity. In this case, the proteins 2B, 3A, and 3B aide in the infection
cycle but are unnecessary for the vaccine (87). We exclude these elements as depicted in Figure
4-1.
To ensure useful, controlled, and high level of protein expression, we included a T7
promoter region 5` of the gene. This allows for expression only in systems that contain the T7
RNA polymerase. Finally, a 6xHis sequence was placed at the C-terminus of the 3C protein to
enable purification and concentrating of the 3C protein, if necessary. The final innocuous gene
design is depicted in Figure 4-1. The NdeI restriction sites were included for facile conversion of
the vector pJ411-P1-3C to be made into pJ411-3C.

4.3.2

Coexpression and Protein Cleavage
In a natural infection cycle, the polyprotein is expressed by the host and then cleaved by

the 3C protein (87). The cleaved structural proteins begin the formation of virus capsids containing
copies of the RNA genome. This process leads to a buildup in the concentration of 3C as more
polyprotein is expressed. Thus, catalytic activity of 3C-mediated cleavage likely increases over
the duration of infection, making it unclear what ratio of 3C to polyprotein is ideal for full cleavage
into the desired products. We therefore designed the system to be capable of coexpressing the
polyprotein and 3C. Controlling the amount of the respective vectors has a direct effect on protein
expression levels.
To analyze the effect of varying protein ratios, we performed CFPS using varying vector
ratios. Figure 4-2 is an example autoradiogram of reactions containing differing vector ratios that
have subsequently been run through SDS-PAGE. The extremes (1:0 and 0:1) demonstrate the
individual expression level from pJ411-P1-3C and pJ411-3C, respectively. The cleavage of the
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polyprotein is apparent, even at the ratio 1:0, suggesting the 3C protein contained in the polyprotein
is sufficient for some extent of protein cleavage. However, noticeable new protein cleavage
products appear when 3C is present at higher concentrations. These cleavage products suggest that
the 3C found in the polyprotein is insufficient for full cleavage of the polyprotein and that some
elevated concentration of 3C protein will aid the full cleavage of the polyprotein.

Figure 4-2 – Autoradiogram of FMD CFPS reactions. To achieve varying protein expression levels, the
plasmids were added in ratios (pJ411-P1-3C to pJ411-3C). The increased level of 3C at 1:1 ratio exhibited a
previously unseen cleavage product, suggesting that the ratio of plasmids could be optimized for maximum
protein yield and cleavage.

4.4

Conclusions and Future Directions
The initial framework has been laid for the rapid production of FMD vaccines. The benefits

of CFPS systems, such as speed to production and controllable gene content, make it a compelling
candidate for rapid vaccine production. The ability to design safe and innocuous genes of virusoriented vaccines is a further benefit that reduces safety hazards and in turn safety costs. This
research could potentially be broadly applicable to FMD and many other virus pathogens that
continue to plague the globe.
This work is being furthered pursued in the Brady Bundy Biotechnology Lab, spearheaded
by Anthony Bennett. The next hurdles for effective FMD vaccine development are 1) proper
assembly of the empty virus capsids, 2) purification of these assembled capsids, and 3) test
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application of these empty virus capsids as a vaccine. This work was funded by the National Pork
Board.
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5

NOVEL VIRUS-BASED NANOPARTICLES

This chapter is an adaptation from the article entitled “The Incorporation of the A2 Protein
to Produce Novel Q[beta] Virus-like Particles Using Cell-free Protein Synthesis” published in
Biotechnology Progress in March 2012. This work was developed and lead by myself and Chad
Varner with the help of Derek Bush.

5.1

Introduction
The development of techniques for protein characterization and production has led to

significant biotechnological advancements in many major industries, including chemicals,
pharmaceuticals, nanotechnologies, agriculture, energy and textiles (123). Commercial proteins
represent a multibillion dollar annual U.S. market and methods to optimize protein production are
continually being investigated (124). In this work, we demonstrate the value of an Escherichia coli
based cell-free protein synthesis (CFPS) system to concurrently 1) directly control the ratio of coexpressed proteins, 2) directly probe the interactions between co-expressed proteins, and 3)
produce cytotoxic proteins to develop novel viral-protein based nanoparticles.
Proteins are traditionally produced in vivo using a wide range of hosts, which enables the
production of myriad proteins (123,125). However, in vivo systems are inherently constrained by
1) the cell wall and 2) susceptibility to cytotoxic proteins. The cell wall prevents direct access to
the cytoplasm, limiting control over the protein synthesis environment. Cytotoxic protein
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production can cause poor cell fermentation growth rates and cell death, lowering overall
production yields (123).
CFPS overcomes these limitations by removing the cell wall, enabling direct control of the
expression plasmid concentration. In addition, the concentrations of chaperones and reagents are
directly controlled, enabling regulation and optimization of synthesis conditions (ionic strength,
pH, temperature, redox potential, etc.) (1,126,127). In some cases, such an open system has
demonstrated higher protein production yields than in vivo systems (32,128). Protein production
is readily scalable and linear DNA expression templates generated by PCR can be used to greatly
reduce the time required for plasmid construction and transformation or genome modification
(1,5,12,129). The native genomic DNA and mRNA are removed from the CFPS environment prior
to protein synthesis, which prevents expression of undesired proteins. This facilitates rapid and
accurate determination of expression yields using small reaction volumes by adding radio-labeled
amino acids to the reaction mixture. As will be demonstrated, relative production yields of multiple
proteins can be assessed at high sensitivity with autoradiography following SDS-PAGE,
eliminating the need for western blotting.
In this work, we demonstrate the use of CFPS to produce viral and cytotoxic proteins
simultaneously, which self-assemble into non-infectious nanoparticles known as virus-like
particles (VLPs) or viral nanoparticles (VNPs). VLPs are engineered for many applications,
including drug delivery (130), biological imaging (131), battery electrodes (132), vaccination
(133,134), and scaffolds for tissue engineering and directed cell differentiation (135). In this
rapidly growing area of research, these applications often necessitate biochemical linkages of small
molecules, polymers, peptides or entire proteins to amino acids exposed on the VLP surface
(136,137). VLPs are typically genome-free virus capsids (outer protein shell), which are composed

52

of many capsomers (one or few subunit proteins bound to create the fundamental subunit of the
VLP) that come together to form highly symmetric icosahedral structures. Due to this repeating
array of capsomers, no linkage site is unique to the entire capsid (Figure 5-1). By controlling
reactant concentrations, a single molecule could be attached to a VLP using a number of
bioconjugation techniques (138). However, by the Poisson probability distribution, the theoretical
maximum of VLPs having a single molecule attached is 37%. The remaining VLP population will
contain zero (37%) or multiple (26%) molecules attached to each VLP and are not easily separated
from VLPs with one molecule.
The bacteriophage Qβ is one of the most stable viruses due to disulfide bond cross-linking
(78,139,140). Disulfide bonding in Qβ increases its thermal stability by more than 50 oC compared
to the non-crosslinked capsid (140). This makes it an attractive candidate for VLP-based
applications. Only the coat protein (CP) is required to form the VLP, where 180 CP self-assemble
into the T=3 icosahedral VLP (78). However, the Qβ virion also naturally contains one unique
protein, the A2 protein (141,142). The A2 protein is incorporated into the virus capsid in a surfaceexposed manner and has two main functions (143). One is to facilitate infection by binding to the
E. coli F-pili (144). The other is to competitively inhibit MurA (an essential enzyme for cell wall
synthesis), which causes the lysis of infected E. coli and the escape of progeny virions (145). In
addition to CP and 1 A2 protein, 3 to 5 A1 proteins are also inserted in the Qβ virus capsid.
However, the mechanism of A2 incorporation and its interactions with the CP, A1, and the
encapsidated genome are not well understood (144,146,147). Also, the tertiary structure of the A2
protein has yet to be determined. Expression and purification of soluble A2 have been problematic
due to its low solubility and cytotoxic function (144,145). In this work, we employ the CFPS
system to control relative expression of the A2 and CP, enabling the optimization of A2
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incorporation into Qβ VLPs. In addition, the A2-CP interaction is probed. This is the first time to
our knowledge that a Qβ VLP has been synthesized de novo, which contains the CP and
incorporates the A2 protein.

5.2

5.2.1

Materials and Methods

Cell-free Protein Synthesis Reactions
Cell free reactions were performed using the PANOxSP system, as described previously

(15). Reaction volumes were either 15 μL in 1.5 mL Eppendorf tubes, or 500 μL in 12-well plates
(Corning, Corning, NY), and all reactions were incubated at 37oC for 3 hrs. Reagents were
obtained from Sigma-Aldrich (St. Louis, MO) and Roche Molecular Biochemicals (Indianapolis,
IN) with the exception of the L-[U-14C] Leucine which was obtained from PerkinElmer
(Waltham, MA). The total plasmid concentration was kept constant at 12 nM using expression
plasmids pY71-Qβcp and pET11a-QβA2 (a kind gift from Catrina Reed and Dr. Ryland Young)
(78,145). Each plasmid has the T7-RNAP promoter directly before the desired genes of the coat
protein and the A2 protein, respectively. No other viral genes were included in the reaction
mixture. E. coli strain KC6 was used to prepare the E. coli cell extract as previously described
(15).

5.2.2

Protein Production Yield Calculations
Total protein production was determined by TCA protein precipitation and radioactivity

measurements on a LS6500 Multipurpose Scintillation Counter (Beckman Coulter, Brea, CA).
Soluble protein yields were found by TCA precipitation and radioactivity measurements of the
supernatant after the reaction was centrifuged for 15 min at 4oC and 17,000 x g. The detailed
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procedure has been described previously (1). The A2 and CP protein production yields from coexpression reactions were determined by TCA protein precipitation and radioactivity
measurements as described above and by analyzing the relative expression with SDS-PAGE,
autoradiography and densitometry. Specifically, the cell-free reaction product was subjected to
SDS-PAGE with NuPAGE 10% bis-tris gels (Invitrogen, Carlsbad, CA) while in the presence of
0.1 M dithiothreitol (DTT) and stained with SimplyBlue SafeStain (Invitrogen), all following
manufacturer specifications. The gels were exposed to Kodak BioMax MR Autoradiography film
(Rochester, NY) for 4-7 days. ImageJ software (National Institutes of Health, USA) was used to
perform densitometry measurements on resulting autoradiograms (148). The A2 and CP are
different sizes (molecular weights of 48.5 kD and 14.1 kD respectively) and migrate to different
locations on the SDS-PAGE gel. Both A2 and CP incorporate C14-leucine and the relative
intensities of the bands on the autoradiogram were used to determine relative co-expression yields.
The co-expression yields of soluble protein was determined following the same procedure with the
inclusion of a 15 min centrifugal spin at 17,000 x g and 4oC to remove insoluble protein.

5.2.3 Purification of Virus-Like Particles
Purification of assembled Virus-Like Particles was performed as outlined previously (1).
To remove all unincorporated 14C-Leucine, the supernatant of 500 μL CFPS reaction product was
immediately dialyzed against 300 mL NET buffer (150 mM NaCl, 5 mM EDTA, and 20 mM TrisHCl, pH 7.8) per mL of reaction in 6-8 kDa MWCO Spectra/Por membrane tubing (Spectrum
Labs, Rancho Dominguez, CA) at 4oC for 24 hrs with 2 buffer exchanges. Dialyzed reactions were
loaded on a continuous 10-40% w/v sucrose gradient prepared using NET buffer in Polyallose
25x89 mm Beckman centrifuge tubes in a manner described previously (149). The formation of
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linear gradients was verified by refractometry using an Atago RX-5000 alpha-BEV refractometer
(Atago, Belleview, WA).
Gradients loaded with CFPS product were centrifuged in a swing-bucket SW-32 Rotor with
a Beckman Coulter Optima L-100 XP ultracentrifuge at 105,000 x g for 3.5 hrs at 4oC. 1 mL
fractions were collected with a Foxy Jr. fraction collector (Teledyne Isco, Lincoln, NE). The
radiation in each fraction was measured with the LS6500 Multipurpose Scintillation Counter to
determine CFPS-produced protein concentration. VLP assembly efficiency was quantified by
comparing CFPS-produced protein in fractions 11-19 to the amount of CFPS-produced protein
added to the gradient (78). Fractions 11-19 were combined and buffer exchanged with NET buffer
by 3 washes of excess NET buffer using Amicon Ultra-4 30,000 MWCO Centrifugal Filter
Devices (78). A final centrifugation at 5,000 x g at 4oC for 25 min was performed to concentrate
the product with the Amicon Filters.

5.2.4

Characterization of Purified Virus-Like Particles
Sucrose gradient fractions 11-19 were collected and concentrated as described above for

individual- and co-expression CFPS reactions. The concentrate was subjected to SDS-PAGE and
autoradiography as specified above. Due to the disparity in A2 and CP concentrations expected in
the VLP (A2:CP ratio of 1:180), 1x, 4x, and 16x serial dilutions were run in parallel on all gels to
ensure proper densitometry measurements were made. Based on these measurements, A2
incorporation efficiency was calculated. A2 is assumed to be incorporated at a maximum of 1 A2
per 1 VLP based on the composition of Qβ virus (141,142,146).
VLPs (purified and concentrated as described above) were analyzed by dynamic light
scattering (DLS) using a 90Plus Particle Size Analyzer (Brookhaven Instruments, Holtsville, NY).
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Raw correlation data was analyzed with Brookhaven Particle Size Analyzing software to give the
mean diameter of the VLPs.
VLPs (purified and concentrated as described above) were also analyzed by transmission
electron microscopy (TEM). The concentrated VLPs were applied to plasma-treated, formvarcoated copper grids and negatively stained with 1% uranyl acetate. Images were digitally captured
using a Tecnai T-12 TEM (FEI, Hillsboro, OR; Gatan, Pleasanton, CA) at 120kV acceleration
voltage. The resulting images and scale bars were sized with ImageJ software (148).
VLP adsorption via A2 was tested as previously demonstrated by Tsukada, et al (150). The
E. coli strain CHS 124, a generous gift from William McCleary (Brigham Young University), was
used in place of the A/λ E. coli strain. VLPs were produced, assembled, purified, and concentrated
from cell-free reactions containing plasmid ratios 0:1 and 1:5 (A2:CP plasmid), as described
above. Adsorption was quantified using radioactivity measurements.
The stability of VLPs produced with and without A2 incorporated (plasmid ratios 0:1 and
1:5) was tested under both oxidizing (7 mM H2O2) and reducing (50 mM DTT) conditions as
previously described(78). Incubation tempertures were 46, 56.8, and 70 oC.

5.3

5.3.1

Results and Discussion

Co-expression of the A2 Protein and the Coat Protein from the Qβ Bacteriophage
To facilitate the assembly of Qβ VLP containing both the coat protein (CP) and the A2

protein (A2), we first sought to assess the impact on protein solubility of the A2 when co-expressed
with the CP. The A2 has been reported to be predominantly insoluble when expressed in vivo
(144,145). The CP is the major component of the Qβ capsid and forms VLPs when expressed
either in vivo or in vitro. The CP is also thought to interact with the A2 to stabilize its incorporation
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into the VLP, although the insertion mechanism and the impact of other interactions are largely
unknown (145,146). Taking advantage of our cell-free protein synthesis (CFPS) system’s ability
to express cytotoxic proteins (such as the A2) and directly control expression plasmid
concentrations, the Qβ CP and the A2 were co-expressed as illustrated in Figure 5-1.
The total plasmid concentration was maintained at 12 nM, while the molar ratios of
plasmids expressing A2 and CP were varied (A2:CP of 1:0, 1:1, 1:2, 1:5, 1:10, 1:20, 1:50, 0:1).
The plasmids for A2 (pET11a-QβA2) and CP (py71-Qβcp) expression were both transcribed by
T7 RNA polymerase during the CFPS reaction (8,78). The relative concentrations selected for this
study of the A2 plasmid compared to the CP plasmid are high compared to the theoretical ideal of
a 1 A2 per 180 CP in the assembled VLP (based on Qβ virus composition). This excess A2 is
likely necessary as 1) not all A2 that is synthesized during viral infection is incorporated into the
virus and 2) previous attempts at producing A2 reported low solubility (144-146).
Figure 5-1 illustrates total and soluble production yields from individual- and coexpression of A2 and CP in the CFPS system as determined by SDS-PAGE, autoradiography, and
densitometry. The cytotoxicity of A2 did not appear to inhibit A2 production since A2 was
produced at a significant yield of 410 ± 50 μg/mL (n=3, ± 1 standard error) when expressed
individually (plasmid A2:CP of 1:0). In comparison, in vivo expression of A2 has been reported
as 0.2 to 0.3 μg/mL (145). Interestingly, the mass yield of CP at 213 ± 29 μg/mL (n=3, ± 1 standard
error) was lower than A2 when CP was expressed individually (plasmid A2:CP of 0:1). However,
the short CP (133 amino acids) is produced at a higher molar yield than the longer A2 (420 amino
acids) (Figure 5-1). The expression difference could be attributed to the disparity in the
consumption of energy required to transcribe the short CP compared to longer A2. It has also been
shown that even small changes in the initial coding sequence of a protein can drastically change
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the production efficiency in a currently unpredictable manner (2). This further warrants the use of
the open environment and high-throughput capabilities of the cell-free system to directly measure
and optimize protein co-expression.

Figure 5-1 – Co-expression of A2 and CP with the CFPS system. (A) Schematic of CFPS reaction. The predicted
A2 structure shown was generated with I-TASSER prediction software. (B) Co-expression results with total
(closed markers) and soluble (open markers) protein production shown for both A2 (triangles) and CP (circles).
Error bares are one standard error with n=3 for all data points.

As shown in Figure 5-1, the CP concentration did not significantly increase with increasing
CP plasmid concentration, suggesting plasmid concentration did not limit CP expression.
However, A2 production varied linearly with A2 plasmid concentration (Appendix C) and A2
solubility was consistently 37 ± 6 µg/mL (n= 15, ± 1 standard error) until total A2 expression
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dropped below this value. Co-expression of the CP did not significantly impact A2 solubility,
while the inverse was observed. Co-expression of A2 dropped CP soluble yields by up to 50%
suggesting some interaction between A2 and CP.

5.3.2

Assembly of A2-incorporated Qβ VLPs
Encouraged by an observed A2-CP interaction, the incorporation of A2 into Qβ VLPs was

probed. Separation of unincorporated proteins from the fully assembled capsids was accomplished
by velocity sedimentation of the reaction products through continuous 10-40% sucrose gradients.
The sedimentation profiles of CFPS reactions, determined by measuring the amount of radiolabeled protein in each collected fraction, are shown in Figure 5-2.
The presence of protein between fractions 11-19 with a peak at fractions 15-16 suggests
the formation of assembled VLPs, as Qβ VLPs have been previously shown to sediment to a
similar location under similar conditions (78). The positive control reaction with CP individually
expressed (plasmid A2:CP of 0:1) has a similar protein profile as the CP-A2 co-expression
reactions, further suggesting the presence of VLPs in these reactions. VLP assembly appears
present in all CFPS reactions with the following exceptions: 1) the co-expression reaction where
CP had the lowest solubility (plasmid A2:CP of 1:1) and 2) the individual A2 reaction (plasmid
A2:CP of 1:0), which served as a negative control. Although CP expression levels remained
relatively constant whether individually- or co-expressed, VLP assembly efficiency was lower in
co-expression reactions. This is likely due to the lower CP solubility observed in the co-expression
reactions (Figure 5-1, Figure 5-2; Table 5-1).
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Figure 5-2 – Velocity Sedimentation Profiles of Product Proteins from CFPS Co-expression Reactions.
Completed CFPS reactions were loaded onto a continuous 10-40% sucrose gradient and centrifuged to separate
assembled VLPs. The radiation in collected fractions was measured to determine the protein concentration
shown.
Table 5-1 – VLP Production Yields and Corresponding Efficiencies of A2 Incorporation
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5.3.3

Characterization of A2-incorporated Qβ VLP
The intrinsic nature of many VLPs is to self-assemble into a monodispersed population of

nanoparticles with a high degree of symmetry. Previously, Qβ VLPs composed of only the CP and
produced and purified using a similar in vitro system were shown to have a similar size and
morphology to those produced in vivo (1,78,151). We thus used Qβ VLPs assembled in vitro from
the CP only (plasmid A2:CP of 0:1) as a standard for VLP size and morphology.
VLPs were purified by collecting Fractions 11-19, shown in Figure 5-2, and concentrated
by membrane filtration. The VLPs purified from a co-expression reaction (plasmid A2:CP of 1:10)
were further characterized using dynamic light scanning (DLS). The presence of nanoparticles was
detected at 29.8 nm ± 6.6 nm (n=10, ± 1 standard deviation, Appendix C) and is consistent with
the published 27 nm diameter of the Qβ VLP (146). The VLPs purified from a separate coexpression reaction (plasmid A2:CP of 1:5) were analyzed by transmission electron microscopy
(TEM) and compared to the VLPs purified from the individual CP reaction (plasmid A2:CP of
0:1) (Figure 5-3). Images of both VLPs reveal particles slightly less than 30 nm, exhibiting a
structure similar to the icosahedral Qβ capsid.
With confirmation of VLP assembly by velocity sedemntation, DLS, and TEM, the
incorporation of A2 was next studied. The purified VLPs from A2-CP co-expression reactions
(plasmid A2:CP of 1:2, 1:5, 1:10, 1:20) and the purified VLPs from the individual CP reaction
(plasmid A2:CP of 0:1) were subjected to SDS-PAGE and autoradiography as shown in Figure
5-4. In addition, fractions 11-19 for the A2-only CFPS sample (plasmid A2:CP of 0:1) were also
collected, concentrated, and subjected to electrophoresis and autoradiography in an identical
fashion as the other samples to serve as a negative control (Figure 5-4). The presence of a protein
band at the expected molecular weight of A2 (48.5 kD) was observed in VLPs produced in co-
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expression reactions but not in VLPs from CP-only reactions. In addition, no such band was
observed in the negative control despite A2 being expressed at yields over twice as high as the coexpression reactions. From these results it appears that A2 is incorporated on the Qβ VLP.

Figure 5-3 – Transmission Electron Microscopy Images of Assembled Qβ VLP. (A) Image of purified Qβ VLPs
from the CP individual-expression CFPS reaction. (B) Image of purified Qβ VLP from the plasmid A2:CP of
1:5 co-expression CFPS reaction. Samples were negatively stained with 1% uranyl acetate.

Figure 5-4 – A2 Incorporation into Assembled Qβ VLP. Lane 1) SDS-PAGE gel protein ladder aligned to the
autoradiograms. Lanes 2-7) autoradiogram of the SDS-PAGE gel containing purified VLP from CFPS
reactions. The presence of the CP dimer was observed in more concentrated 1:20 and 0:1 A2:CP samples due
to insufficient denaturing.
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The incorporation efficiency of A2 into the Qβ VLP was determined by subjecting serial
dilutions of the purified VLPs to SDS-PAGE, autoradiography, and densitometry. The results are
shown in Table 5-1, with the plasmid A2:CP of 1:5 reaction exhibiting the highest incorporation
efficiency of 1 A2 to 1.03 VLPs, which is similar to the predicted theoretical maximum of 1 A2 to
1 VLP (based on Qβ virus composition) (141,146). Although it cannot be precluded that some
VLP might incorporate more than one A2, it is likely that the VLP capsid behaves like the viral
capsid. Previous works support a strong similarity between the Qβ virus and the Qβ VLP
(1,78,151). In addition, the data support the hypothesis of a limited number of A2 per molecule.
Despite the presence of excess soluble A2 (1 soluble A2 per ~9 soluble CP produced compared to
the 1 A2 per 180 CP in the Qβ virus), incorporation efficiencies never exceeded 1 A2 per 1.03
VLP.
From these results, it appears that the A1 protein and the genome are not essential for
efficient A2 incorporation. Also, as shown in Table 5-1, the incorporation of A2 was not nearly as
efficient at higher and lower ratios of A2:CP. This suggests a careful balance between the
expression of A2 and CP is necessary for efficient A2 incorporation. The observation is not entirely
surprising, considering only ~2% of the A2 produced during infection is incorporated into
infectious virions (145).
In the naturally occurring virus, the incorporated A2 protein is surface exposed, enabling
it to bind with the F pilus of E. coli (143,150). We hypothesized that the A2 incorporated into the
VLP would exhibit the same adsorption if it is also surface exposed. Using methods previously
demonstrated by Tsukada, et al., adsorption of VLP with A2 was found to be significantly higher
than VLP without A2 (Appendix C). This suggests that the A2 in many if not all the VLPs is
surface exposed and maintains its functionality of binding the F Pilus.
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Finally, we explored the effect of A2 incorporation on the thermal stability of the VLP. It
has been demonstrated that the formation of disulfide bonds amongst the 180 CP of the Qβ VLP
significantly increase its stability (78,140). However, the effect of A2 on VLP stability has not
been explored. VLPs were produced, assembled, purified and concentrated from cell-free reactions
containing plasmid ratios 0:1 and 1:5 (A2:CP plasmid). The VLPs were incubated with 7 mM
H2O2 or 50 mM DTT to stimulate the formation or dissolution of disulfide bonds as previously
reported (78). The incorporation of A2 did not seem to significantly alter the thermal stability of
the oxidized (H2O2-treated) or reduced (DTT-treated) VLP (Appendix C).

5.4

Conclusion
We have demonstrated the utility of CFPS for directly tuning the relative expression levels

of multiple proteins for the optimal production of self-assembling multi-protein macromolecular
complexes. Additionally, the cytotoxic A2 protein was produced at significantly higher yields than
previously reported for in vivo production, demonstrating the efficacy of CFPS for cytotoxic
protein production. Co-production of A2 and CP resulted in the incorporation of A2 into the selfassembling Qβ VLPs without the presence of A1 protein and genomic RNA. By varying the A2CP plasmid ratio, the relative expression levels of A2 and CP were optimized to produce A2incorporated Qβ VLPs, approaching the theoretical maximum efficiency of 1 A2 per VLP. This is
the first time to our knowledge that the CP-based Qβ VLP has been produced de novo to
incorporate A2. The production of novel VLPs with unique surface accessible proteins, such as
the one produced in this work, could enable more controlled engineering of VLPs for a growing
assortment of applications.
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6

STABILIZED PROTEIN THROUGH SITE-SPECIFIC IMMOBILIZATION

This chapter is an adaptation from the article entitled “Enhanced Protein Stability Through
Minimally Invasive, Direct, Covalent, and Site-specific Immobilization” published in
Biotechnology Progress in January 2013. This work was developed and lead by myself and Jeffrey
Wu with the help of Chad Varner.

6.1

Introduction
Proteins represent a $100+ billion USD industry with rapid annual growth (152,153). The

utilization of proteins for bioprocessing, sensing, and medical treatment is widespread over a
number of industries including agricultural, textile, pharmaceutical, energy, and chemical
processing (154-156). Proteins have a number of advantages over non-biological chemicals and
chemical processes due to: 1 superior chemo-, regio-, and stereospecificity of enzymes (154,157159); 2 green sustainability (renewable, biodegradable, non-toxic, milder reaction conditions, less
energy consumption) (154,156,160-162); and 3 optimization through protein engineering
(163,164). However, difficulties in recovery, reuse, and long-term stability limit the far-reaching
industrial potential of proteins (165). Protein immobilization is a potential solution as it simplifies
protein recovery and reuse, and reportedly increases protein stability in many cases (155,159,165).
This work is focused on improving protein immobilization and we introduce the Protein Residue-
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Explicit Covalent Immobilization for Stability Enhancement or PRECISE system that enables the
targeted immobilization of proteins to enhance protein stability and durability.
The most robust immobilization techniques for protein-surface bioconjugations are
covalent (166,167). However, precisely controlling which location on the protein covalently binds
to a surface is complicated by the naturally limited pool of only 20 amino acid building blocks.
Covalently targeting a given amino acid which appears in multiple locations in a protein commonly
results in undesirable attachment orientations and loss of activity and stability (168-170).
A number of site-specific yet non-covalent approaches have demonstrated superior activity
using recognition pairs such as 6His/Ni (171), biotin/streptavidin (172), more generally
oligonucleotide/protein (173). However, long-term stability and reusability are compromised due
to protein leaching that is further exacerbated under industrially relevant conditions (169). In
addition, such systems commonly require the fusion of large tags which can negatively affect
protein structure and function especially if inserted at locations other than the terminus (169,174).
Increasingly, research efforts have focused on developing both a covalent and site-specific
immobilization technique. Specific targeting of the C and N termini for conjugation to peptide tags
has been successfully reported with tags such as transglutaminase (175) and phosphatase (176),
yet remains insufficient in cases where the termini are critical to protein folding and/or function.
To target residues within the protein, complete elimination of all similar residues and chemical
moieties except at the desired conjugation site can enable site-specific covalent linkage (168).
However, mutagenesis of this magnitude is typically destabilizing. Alternatively, unnatural amino
acids (uAAs) provide unique functional groups which can react with a number of bioorthogonal
and highly efficient reaction chemistries such as click chemistry, the Staudinger reduction, and
Diels-Alder reaction-like cycloadditions (169,170,177). Global replacement of a natural amino
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acid with an uAA analogue achieved by omission of the natural amino acid during protein
synthesis is commonly performed, although, site-specific immobilization is still complicated by
the incorporation of the unnatural amino acid at many locations (178,179).
The PRECISE system overcomes the reported issues of non-specific and non-covalent
immobilization by building upon a developed technology that site-specifically incorporates a
single uAA at a single explicitly predetermined residue (77,180). This technology was initially
developed as an in vivo Escherichia coli-based system that uses orthogonal tRNA and aminoacyltRNA synthetase from Methanocaldococcus jannaschii to incorporate the uAA only in the location
encoded by the amber stop codon (UAG) on the mRNA (180,181). Using this method, over 70
uAA have been incorporated with generally high selectivity (182,183). Two particularly attractive
unnatural amino acids are p-propargyloxyphenylalanine (pPa) and p-azidophenylalanine (pAz)
which can be used with the highly selective, efficient, and biocompatible copper(I)-catalyzed
azide-alkyne [3 + 2] cycloaddition click reaction. Due to the photoinstability of pAz, this work
focuses on the incorporate pPa to enable direct click chemistry to the surface.
Using the in vivo site-specific insertion technique, Kim et al. targeted a predetermined
residue location in the protein DrrA and clicked an alkyne-biotin with site-specifically
incorporated pAz (184). The biotin-linked protein was them surface-immobilized by the noncovalent neutravidin-biotin interaction. Compared to randomly-oriented immobilized DrrA, the
orientation-specifically immobilized DrrA exhibited higher activity of DrrA (184). Although Kim
et al. demonstrated the capability of residue-explicit targeting, the non-covalent link limits the
immobilization’s robustness.
The PRECISE system uses site-specific uAA and direct covalent immobilization,
eliminating the need for a non-covalent linker. In addition, the photostable pPa is incorporated
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using an E. coli-based cell-free protein synthesis (CFPS) approach that eliminates membranetransport limitations and has resulted in up to a 27 fold increase in protein production yields for
proteins containing pPa (8). Other advantages of CFPS include direct access and optimization of
the synthesis environment, simplified purification, and high-throughput automation potential
(49,78,185).
The site-specific covalent surface immobilization of proteins presented herein provides a
unique balance of stable protein binding and orientation control without the need of non-covalent
linkers. While the technology for the site-specific incorporation of pPa using cell-free protein
synthesis has been previously reported (8), here we report the application of this technology for
site-specific immobilization of proteins onto non-protein surfaces such as superparamagnetic
beads. Our results also indicate extended longevity and stability of active bound proteins under
biologically-unfavorable conditions with potential implications for industrial biocatalysis, protein
microarrays technologies and other protein based diagnostic applications.

6.2

6.2.1

Materials and Methods

Extract Preparation
E. coli extract was prepared using a BL21 Star™ (DE3) E. coli strain purchased from

Invitrogen (Carlsbad, CA) harboring the pEVOL-pPrF plasmid, a kind gift from Peter Schulz,
(Scripps Research Institute). The resulting E. coli strain produces the Methanocaldococcus
jannaschii aminoacyl-tRNA synthetase/tRNA pair capable of recognizing and inserting pPa at the
amber stop codon AUG (77). Cell extract was prepared as previously reported (8,78) with the
following modifications. The strain was fermented in 1 L batches of 2xYT media buffered with
100 mM MOPS at 37° C and shaken in a 2.5 L Tunair baffled shake flask (IBI Scientific, Peosta,
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IA) at 280 rpm. Cells were lysed through triple pass homogenization using an Avestin Emulsiflex
B-15 cell disruptor (Ottawa, Canada) at 21,000 psi. Subsequently, the remaining cell extract was
flash-frozen and stored at -80° C until used.

6.2.2

Cell-Free Protein Synthesis
Protein synthesis of T216pPa sfGFP (pPaGFP) was carried out in vitro using the PANOx-

SP system as previously described (8) with the following minor modifications. Plasmids used were
either pY71-sfGFP-Strep or pY71-T216Amb-sfGFP-Strep (8). Unless specified, all reactions
contained 2 mM pPa. BL21 Star™ (DE3) E. coli extract was added at 25% v/v, without additional
T7 RNA polymerase. Reactions contained 7 μg/mL Methanocaldococcus jannaschii aminoacyltRNA synthetase affinity purified according to a previously reported procedure (9). Reactions were
performed at 30 oC for 8 hours or overnight.

6.2.3

Protein Yield Assays
Total and soluble protein yield calculations were performed using liquid scintillation

counting as discussed previously (1,19,186). An analysis of full-length protein yields was
performed by first running sodium dodecylsulfate polyacrylamide gel electrophoresis on the
supernatant of the CFPS reaction mixtures after centrifugation at 13,000 xg for 15 min, and on
strep-column purified protein as per the manufacturer’s specifications (Life Technologies,
Carlsbad, CA). Autoradiograms were prepared on Kodak MR Autoradiography Films (Rochester,
NY) and densitometry calculations were performed using ImageJ software (148).
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6.2.4

Fluorescence Activity Assay
Fluorescence assays were performed using a Synergy MX (Biotek Instruments, Winooski,

VT) at 485/510 nm excitation/emission and sensitivity of 100 in 60 or 125 μL of PBS buffer per
well of a black-bottom 96-well plate.

6.2.5

Dynabead Preparation
The superparamagnetic M-270 Dynabeads decorated with terminal amines were reacted with

azide-containing ligands, using a procedure adapted from Punna et al. (187). First, 4-nitrophenyl
5-azidopentanoate was synthesized through the addition of 5-azidopentanoic acid (3.5 mmol) and
p-nitrophenol (3.7 mmol) to a solution with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (3.7 mmol) in CH2Cl2 at room temperature overnight. The 4-nitrophenyl 5azidopentanoate was then concentrated and purified using silica gel column chromatography.
After purification, the 4-nitrophenyl 5-azidopentanoate was dissolved in DMF and added to
a tube containing 2 ml of Dynabeads (2x109 beads per ml) in 5% MES buffer and stirred gently at
room temperature for two days. Measurement of the released p-nitrophenol absorbance at 412 nm
was then performed and compared to a p-nitrophenol standard curve. A negative control reaction
containing no beads (no amines) was performed and no change in 412 nm absorbance was
observed suggesting no autohydrolysis of the 4-nitrophenyl 5-azidopentanoate. Beads were
vigorously washed 10 times with PBS buffer to remove excess and non-specifically adsorbed azide
ligand.

6.2.6

Click Reaction (Copper-catalyzed Azide-Alkyne Cycloaddition)
The aqueous click reaction conditions were performed with either 1 mM CuSO4 and 5 mM

sodium ascorbate or 1 mM tetrakis(acetonitrile)copper(I) hexafluorophosphate (Cu(I)Tet) for
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CuSO4 or Cu(I)Tet catalyzed reactions, respectively. Click reactions with Alexa Fluor® 555
alkyne (AF555) (Invitrogen, Carlsbad, CA) were performed exclusively with Cu(I)Tet with 0.2 to
20 nmol of AF555 in 30-50 μL reaction volumes. The reaction volume for click reactions with
pPaGFP was 100 μL with 0.5 nmol pPaGFP and 5 nmol azide-functional groups in the reaction.
Reagents were prepared aerobically in microcentrifuge tubes with all components save the
catalyst and sodium ascorbate. Tubes were then transferred to an anaerobic glove box atmosphere
containing less than 0.0 ppm oxygen and allowed to degas for a minimum of 45 minutes. After
degassing, catalyst and, if required, sodium ascorbate was added. The closed tubes were then
rotated end-over-end for 8 to 14 hrs in darkness. Reactions were terminated by removal of the
tubes from the anaerobic glove box and exposure to atmospheric oxygen.

6.2.7

Purification of Click-immobilized pPaGFP
To purify the superparamagnetic beads from the click reaction solution, a DynaMag Spin

Magnet (Invitrogen, Carlsbad, CA) was used as follows. The microcentrifuge tubes containing the
click reaction were placed on the DynaMag Spin Magnet for 8 mins, after which the supernatant
was removed. The tubes were then removed from the magnet, 100 μL PBS-Tween buffer (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 0.05% v/v Tween20) was added to the
samples, the samples were thoroughly vortexed, and the new suspensions were incubated for 8
mins at room temperature. Samples were returned to the DynaMag Spin Magnet and the cycle was
repeated 2 times. After the final removal of the supernatant, the sample was re-suspended in 100
μL PBS.
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6.2.8

Freeze Thaw
pPaGFP was immobilized on azide-functional Dynabeads using both CuSO4 and Cu(I)Tet

and purified as described above. In a single black 96-well plate (Plate A), both pPaGFP
immobilized on beads and free pPaGFP was aliquoted into different wells to a final volume of 60
μL in PBS buffer. In a separate black 96-well plate (Plate B), free pPaGFP was aliquoted into
different wells to a final volume of 60 μL in PBS buffer. Plate A was subjected to four freeze-thaw
cycles by incubating it at -80oC for 20 min and then incubating it at room temperature for 20 min.
Between each freeze-thaw cycle fluorescence measurements of the pPaGFP were taken with the
Synergy MX microplate reader as described above. Concurrently, Plate B was incubated at 4oC
and fluorescence measurements of the pPaGFP were also taken every 40 min.

6.2.9

Urea/Heat Incubation
pPaGFP were immobilized on azide-functional Dynabeads using both CuSO4 and Cu(I)Tet

and purified as described above. In a single black 96-well plate (Plate C), both pPaGFP
immobilized on beads and free pPaGFP were aliquoted into different wells to a final volume of 50
μL in PBS buffer. To all wells containing pPaGFP immobilized on beads and to half of the wells
containing free pPaGFP was added 75 μL of 10 M urea, bringing the final urea concentration to 6
M. To the remaining wells of free pPaGFP was added 75 μL of deionized sterile water in place of
urea. In a separate black 96-well plate (Plate D), free pPaGFP was aliquoted into different wells
to a final volume of 50 μL with PBS buffer following which 75 μL of deionized sterile H2O was
added.
Immediately after adding urea or water, Plate C was placed in the Synergy MS microplate
reader with the sample chamber temperature maintained at 50oC and assayed for fluorescence
activity every minute for 30 mins. The plate was removed from the plate reader and cooled to 4oC
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and assayed for fluorescence activity after 1.5 and 12 hrs. Place D was treated in a similar manner
with the exception of the microplate reader’s sample chamber temperature being maintained at
room temperature.

6.3

Results and Discussion
The Protein Residue-Explicit Covalent Immobilization for Stability Enhancement or

PRECISE system introduced herein allowed for retention of protein activity and increased the
stability and durability of the proteins. Azide-functional superparamagnetic beads were prepared
as the attachment surface and tested using small alkyne-functional fluorophores. Then, GFP
containing an unnatural amino acid (uAA) was synthesized, purified, and successfully
immobilized to the beads with the PRECISE system as illustrated in Figure 6-1. Immobilized GFP
maintained a significant fluorescence activity and exhibited increased stability against freeze-thaw
cycles, urea and elevated temperature compared to unbound GFP, as will be described in detail
below.

6.3.1

Preparation of Azide-Functional Surface
Superparamagnetic beads were selected as the immobilization surface for simplicity in

purification, recovery, and reuse. Furthermore, they provide a macro, inorganic surface for
conjugation. Amine-decorated superparamagnetic beads (Dynabeads® M-270, Invitrogen) were
modified with terminal azide groups as shown in Figure 6-2. To make the beads viable reagents in
the click reaction, the amine-coated beads were reacted with 4-nitrophenyl 5-azidopentanoate and
the release of p-nitrophenol was measured by absorbance to determine extent of reaction, which
resulted in azide-functionalization of 95% of the amine groups available as per the manufacturer’s
specifications (Invitrogen).
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Figure 6-1 – Scheme of the PRECISE System

Figure 6-2 – Scheme of Azide Decoration of the Superparamagnetic Beads.

6.3.2

Cell-free Protein Synthesis
Superfolder Green Fluorescent Protein (sfGFP) was rationally engineered to incorporate

an uAA at T216 and to contain a C-terminal purification tag (8). The site T216 was chosen for
substitution by identifying a surface-accessible protruding loop near an end of the cylindrical
76

protein’s crystal structure (Figure 12-1). The C-terminal Strep-tag provided means of purifying
full-length protein from truncated product, which occurs when the uAA is not incorporated and
results in early termination of the protein (Figure 6-3). By carefully choosing the location of
mutagenesis and avoiding alterations to the main structural or active portions of the protein, the
potential for improper folding or activity loss is minimized. Indeed, the activity of purified uAAcontaining sfGFP did not drop compared to the activity of unmodified sfGFP (8).

Figure 6-3 – SDS-PAGE and Autoradiogram of pPaGFP. The lanes are laid out from left to right as follows: 1)
pPaGFP post-Strep-tag purification; 2) synthesized pPaGFP prior to purification; 3) pPaGFP synthesized
without the presence of pPa; and 4) unmodified sfGFP synthesized under otherwise identical conditions to
other products.

The PRECISE system utilizes the open access afforded by CFPS to optimize
concentrations of the Methanocaldococcus jannaschii aminoacyl-tRNA synthetase (Figure 12-2),
which works together with its tRNA pair to incorporate the uAA pPa at the Amber stop codon. As
displayed in Figure 6-3, pPa was successfully incorporated approximately 40% of the time when
pPa was present in the CFPS reaction. When pPa was absent, the protein was truncated at the
amber stop codon with no detectable incorporation of pPa (Figure 6-3, Lane 3), which is consistent
with previously reported works (8,188,189).
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The CFPS production approach has specific advantages over in vivo protein production
such energy focused toward expression of the product protein(s), simplified product purification,
and elimination of transport-limiting cell-walls (8,19,78). In addition, CFPS enables direct access
to the open synthesis environment and enables facile optimization and maximization in the
concentration of synthetase, uAAs, and other cofactors essential for protein synthesis.

6.3.3

Click Immobilization
Preliminary click immobilizations to the beads exploring click conjugation efficiency were

performed using a small fluorescent ligand, Alexa Fluor® 555 alkyne (AF555). Click conjugation
was successful under multiple reagent concentrations as seen in Figure 6-4. Reactions containing
1 nmol or more AF555 resulted in the highest amount of immobilization. At 5 and 20 nmol AF555,
the resulting attachment was not statistically higher than at 1 nmol (p-value = 0.78). This apparent
maximum results in an average of 12 million AF555 per bead. The number of AF555 attached and
the percentage attached in Figure 6-4 are conservatively reported and do not account for signal lost
due to light diffraction and shadowing caused by the beads.
Reaction conditions for pPaGFP immobilization were selected based on AF555 results.
pPaGFP were immobilized onto the azide-functional magnetic beads by anaerobic incubation
using reduced copper from either CuSO4 or tetrakis(acetonitrile)copper(I) hexafluorophosphate
(Cu(I)Tet) as a catalyst. The results are reported in Table 6-1. The Cu(I)Tet-catalyzed reactions
resulted in a higher click attachment percentage at 11% (9.6 million pPaGFP per bead), compared
to the CuSO4-catalyzed reactions at 4.5% (3.9 million pPaGFP per bead). The two catalyst systems
provide the essential catalyst (Cu(I)) with differing mechanisms. Cu(I)Tet provides Cu(I) directly
while the CuSO4 system relies on the redox potential of sodium ascorbate to reduce Cu(II) to Cu(I).
The divergence in catalyst-recovery mechanisms is a likely cause for the mild divergence in overall
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reaction efficiency. While high reaction efficiencies are reported in literature for similar click
reactions using protein reagents (178,190,191), the reagent concentrations used in this work are at
least an order of magnitude lower. Excellent work by M.G. Finn’s lab (Scripps Research Institute)
has demonstrated that the optimal copper catalyst concentration is dependent upon the reagent
concentration (190,192). In addition, Finn and others have reported a variety of ligands which
improve the kinetics and reaction efficiency and the optimal concentration of such ligands can
depend on the reagent types and concentrations (190,192). Further work to optimize the click
reaction at the lower concentrations used in this work, could substantially increase the reaction
efficiency. However, we do observed significant pPaGFP attachment with the reported reaction
conditions.

Figure 6-4 – Alexa Fluor® 555 and Bead Click-Conjugation Profile. The number of AF555 attached and the
percentage attached are conservatively reported above and do not account for signal lost due to light diffraction
and shadowing caused by the beads. “Percentage AF555 Attached” refers to the percentage of AF555 attached
compared to the amount input into the reaction solution. No Background attachment of AF555 to beads was
evident under any of the conditions considered. Error bars = standard deviation (n=2) or none (n=1).

79

After washing the beads with PBS-Tween buffer three times, non-specific adsorption was
insignificant. However, washing with PBS only resulted in some non-specific adsorption (0.5
million pPaGFP per bead as compared to 3.9 and 9.6 million pPaGFP per bead attached via click
conjugation) (Figure 12-3).
Table 6-1 – pPaGFP Attachment and Observed Activity Values

The cyclo-addition of azides to non-activated alkynes is Cu(I)-catalyzed to avoid high
pressures and temperatures that would be incompatible with biological systems (193). However,
copper ions can quench GFP fluorescence by direct, non-denaturing interaction with the
chromophore (194,195). In addition, it is difficult to accurately assess the specific activity of the
immobilized protein due to the complicating factors of bead-induced light diffraction and
shadowing, which may cause up to 50% signal reduction. However, based on the very conservative
assumption that all active pPaGFP on the bead were observed (i.e. no loss due to the bead-induced
light diffraction and shadowing), immobilized pPaGFP retained at least 40% of the activity of the
free pPaGFP incubated in the click reaction environment. For clarity, when reporting the stability
of immobilized pPaGFP and free pPaGFP under the harsh conditions below, changes in activity
per mol pPaGFP are reported to eliminate the impact of bead-induced signal loss factors.
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6.3.4

Freeze Thawing
To evaluate if the immobilized pPaGFP exhibited improved stability, free pPaGFP and

bead-immobilized pPaGFP were subjected to multiple cycles of freezing and thawing. Changes in
pPaGFP activity were normalized per mol pPaGFP and are reported in Figure 6-5. The beadimmobilized pPaGFP activity increased slightly over the 4 freeze-thaw cycles. In contrast, freezethawed free protein lost an average 17% of the initial activity after each cycle, resulting in a 68%
loss in activity after 4 freeze-thaw cycles. Free protein kept at 4 oC over the entire experiment also
resulted in a drop in activity after 4 cycles. Free proteins subjected to freeze-thaw or maintained
at 4 oC in the presence of the copper-catalyst of the click reaction exhibited very similar trends as
their copper-free counterparts (Figure 12-4).

Figure 6-5 – Freeze Thaw Effects on Stability. Bead-conjugated pPaGFP were run in parallel through freeze
thaw cycles (20 min at -80oC, 20 mins at 25oC, assay, repeat) following which the fluorescence activity was
assayed. In addition, a control for the behavior of free pPaGFP consisted of free pPaGFP either freeze-thawed
(solid-line, circles) or maintained at 4oC (dashed line, circles). Error bars = standard error (n=2 for beads, 26
for freeze-thawed, 50 for control).
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6.3.5

Urea/Heat Incubation
Bead-immobilized pPaGFP and free pPaGFP were incubated under the harsh conditions of

urea (6 M) and elevated temperature (50 oC). Resulting changes in activity were normalized per
mol pPaGFP and are reported in Figure 6-6. Bead-immobilized proteins retained 57% or more of
their initial activity throughout the duration of the incubation in urea at 50 oC. After the samples
were cooled to 4 oC, the activity of immobilized pPaGFP recovered 83% or more of the initial
value, despite continued incubation in urea. In contrast, free pPaGFP retained less than 10% of
their initial activity during heating and after 12 hours of cooling exhibited less than 3% of the
initial activity, regardless of urea’s presence or absence.

Figure 6-6 – Urea and Heat Effects on Stability. Bead-conjugated pPaGFP were run against multiple controls
and assayed for fluorescence. The solutions, with the exception of the free pPaGFP at room temperature, began
at room temperature and were incubated at 50oC for the duration of the assay (30 min) directly after addition
of room-temperature urea or water. After the initial 30 minute assay, samples were placed at 4oC until the next
data point was read. The addition of urea caused the free pPaGFP to drop in activity prior to any heating
(empty circles). The bead-immobilized pPaGFP did not exhibit any immediate loss in activity due to the
addition of urea (empty squares/diamonds). Error bars = standard error (n=2 for bead-conjugated pPaGFP,
n=3 for free pPa GFP, and n=4 for free room temperature pPaGFP).
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6.4

Conclusion
We have introduced an example of Protein Residue-Explicit Click Immobilization for

Stability Enhancement or the PRECISE system. Click chemistry teamed with minimally invasive
site-specific uAA-incorporation using cell-free protein synthesis allowed for the rationally
engineered protein to be directly and site-specifically immobilized onto an inorganic surface. In
all cases explored here, the immobilized pPaGFP appeared to exhibit superior stability, durability
and retained activity during multiple harsh scenarios as compared to free protein in solution.
The ability to site-specifically attach proteins to a surface using bio-orthogonal chemistry
at any predetermined site has provided a basis for more stable and longer lasting protein activity.
This technology has numerous implications in the industrial, scientific and medical communities
and could be applied to enhance industrial enzyme recovery, simplify laboratory assays and
machinery, and reduce medical diagnostic costs while increasing consistency, availability and
transportability. Furthermore, this work solidifies the foundation for the PRECISE system for
highly stable protein immobilization.
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7

7.1

EXPANDING THE LANGUAGE OF BIOLOGY: SENSE CODON REASSIGNMENT

Introduction
The 23 proteomic amino acids have provided for rich biological diversity on earth (196).

Yet the narrow range of chemistries provided by these residues can frequently pose a challenge to
the biochemist’s quest for site-specific modifications to protein. The site-specific incorporation of
unnatural amino acids (uAAs) in proteins unlocks the potential for unique residues. This rapidly
growing field provides a unique tool that has already been applied toward improving
pharmacokinetics, cancer treatments, vaccine development, proteomics and protein engineering
(20,183,197-204). In short, the ability to site-specifically incorporate uAAs is a strong platform to
expand the chemistry of life (8,9,180,183). Although decades of work have been devoted to this
area of research, major strides have recently been made toward simple, productive, and readily
transferable methods of site-specific uAA-incorporation (10,21,49,66,205). Most notably, Shultz
and coworkers have developed a number of evolved aminoacyl tRNA-synthetase/tRNA pairs that
act orthogonally to native synthetase/tRNA pairs, allowing for high fidelity protein synthesis
without interactions between native and evolved synthetase/tRNA pairs. These evolved
synthetases incorporate the uAAs site-specifically at Amber codons (180,183,206). Over 70 uAAs
have been incorporated with high specificity using this system (183).
One considerable challenge with current uAA incorporation techniques is the limited
availability and efficiency of uAA-codons. Amber stop codons are predominantly targeted with
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some examples of opal and frame-shift codons being successfully employed (77,183). However,
these systems suffer from competition of endogenous systems (release factors or native tRNA) and
therefore have only achieved low efficiencies compared to naturally occurring coding efficiency
(207). Furthermore, the limited selection of codons restricts the number of different uAAs that can
be incorporated simultaneously. To more richly expand the language of biology, new unique
codons must be identified and made available.
This work proposes a CFPS system that would be capable of simultaneously recoding up
to 43 uAAs as well as the 20 universal natural amino acids. To achieve this goal, the following
criteria must be fulfilled:
1. Removal or degradation of endogenous tRNA from cell extract
2. Development and expression of synthetic minimal tRNA set for natural AAs
3. Harness orthogonal aminoacyl-tRNA synthetase/tRNA pairs for uAA incorporation
Removing the endogenous tRNA from the cell extract effectively removes the link between
native tRNA aminoacylation and the genetic code, opening the possibility to completely recode
the relationship between codons and amino acids.
Development of a synthetic minimal tRNA set restores a minimalistic relationship between
codons and amino acids. The synthetic minimal set should be sufficient to encode for the 20
universal amino acids, leave one codon for peptide synthesis termination while leaving up to 43
of the 64 total codons available for reassignment to uAA incorporation.
The final step to develop the system is to harness the power of aminoacyl-tRNA
synthetase/tRNA (aaRS/tRNA) pairs that are orthogonal to our bacterial system. Orthogonal
aaRS/tRNA pairs do not interfere with the synthetic minimal set tRNA, native aaRSs, nor natural
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amino acids. The successful execution of such a system has the potential to disrupt current uAAincorporation technology and open a new field of protein research otherwise impossible.

7.2

7.2.1

Results and Discussion

Removal of Endogenous tRNA
This first step to reassign the codons of our system is to remove the endogenous tRNA,

effectively removing the connection between codon and amino acid. A study by Kanda and
coworkers reported that incubating cell-extract with RNAse A effectively removes tRNA and shuts
off the extract’s protein synthesis capabilities (208). Kanda further reported that protein synthesis
capabilities could be restored upon addition of mixed endogenous tRNA to the extract. These
promising results laid the foundation for our tRNA degradation protocol.
To simplify the tRNA degradation protocol, RNAse A protein was immobilized on
superparamagnetic beads (Dynabead M270, Life Technologies, Grand Island, NY) using aminetargeting epoxy groups. The superparamagnetic beads provided an easy mechanism for removal
of the RNAses prior to addition of nucleic acids required for protein synthesis. Treatment of the
extract resulted in extract without protein synthesis capability (Figure 7-1A). Addition of mixed
endogenous tRNA to the extract resulted in recovery of protein synthesis viability. The beads with
RNAse A immobilized are reusable, decreasing the overall cost of the treatment system (Figure
7-1B). This system is an effective method for removing tRNA from cell-extracts.

7.2.2

Design and Production of Synthetic Minimal tRNA Set
The design of a synthetic minimal set of tRNA is the next step in developing a native codon

reassignment system. Twenty-one codons must be reserved for the 20 universal natural amino
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acids and a single stop codon. The 20 amino acids each require one unique tRNA. In addition,
protein synthesis requires a specialized tRNA for initiation. The stop codon requires no tRNA.
Therefore, a synthetic minimal set capable of encoding for the universal 20 amino acids must have
at least 21 synthetic tRNA.

Figure 7-1 – Extract Performance after RNAse A Treatment. Extracts were incubated in the presence of beads
with RNAse A covalently immobilized. (A) Comparing the performance of the treated extract with or without
mixed Escherichia coli tRNA added. (B) Recycling the treatment beads for multiple treatments. All cycles were
sufficient to prevent protein synthesis in the absence of mixed tRNA.

To avoid the necessity of engineering novel tRNA and their respective aaRS pairs, it is
preferable to utilize the available endogenous aaRSs. Thus, the synthetic tRNA should be based
primarily on known native tRNA sequences. One difficulty of directly copying the native genes is
the question of sufficient expression levels. Native tRNA are promoted with a variety of promoters
and terminators, and are often found in operons of other tRNA and mRNA for proteins. After
transcription, many tRNAs are cleaved into their respective final formats. Employing native
promoters would be troublesome in our CFPS system, as the endogenous RNA polymerases would
likely be insufficient to obtain useable levels of tRNA.
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To combat the problems of expression levels and post-transcriptional cleavage, we propose
the use of a transfer RNA ribozyme construct, or “tranzyme.” Fechter and coworkers demonstrated
that synthetic tRNA could be promoted for transcription at high levels using a T7 promoter
sequence in combination with a hammerhead ribozyme (HHR) (209). The HHR has autocatalytic
activity that is capable of cleaving the transcribed product, resulting in proper tRNA products.
Albayrak and coworkers demonstrated the versatility of this concept by developing further
successful tranzyme products (38). Based on these reports, we designed a template for our
tranzyme, depicted in Figure 7-2.

Figure 7-2 – tRNA “Tranzyme” Gene Designs. The design of the synthetic tRNA was produced such that the
5` and 3` ends of the final RNA product would have the appropriate termini for tRNA. The hammerhead
ribozyme cleaves the 5` end appropriately, while the 3` end is digested prior to transcription to allow the T7
RNA polymerase to terminate transcription by releasing the DNA rather than using a T7 terminator sequence.

Selecting the tRNA sequences to include in our minimal set was based on iterative analysis
of the following criteria:
1. Is the endogenous sequence known and available?
2. Does the tRNA anticodon experience promiscuous binding with multiple codons?
3. What is the Escherichia coli Class II codon bias for the pairing codon(s)?
The availability of the endogenous sequence is essential to take advantage of endogenous
aaRSs. If the tRNA is promiscuous in its binding with codons, then a single tRNA could disallow
multiple codons for uAA-incorporation. Therefore, preference is given to tRNA that are less
promiscuous, thus leaving more available codons for reassignment.
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Regarding codon bias, it has been established that tRNA content and codon bias are
positively correlated (210). This would suggest that a codon with a high bias (i.e. one used more
frequently in the genome of the expression host) would have more pairing tRNA available.
Assuming our tRNA degradation method is not 100% efficient at removing all active tRNA, logic
suggests that the remaining tRNA would be those found initially at high concentrations. Choosing
these tRNA sequences and codons as part of our minimal set reduces the risk of interference from
residual endogenous tRNA. Based on these criteria, we have selected a synthetic minimal set of
tRNA for our codon reassignment system.

7.3

Conclusions and Future Directions
The initial framework has been cobbled for the development of a CFPS system capable of

simultaneous incorporation of multiple unnatural amino acids using sense codon reassignment.
The ability to directly access and manipulate the transcription/translation environment of CFPS
has made it possible to degrade native tRNA and replace it with mixed endogenous tRNA. The
design of a synthetic tRNA set lays the foundation for future work.
Continued pursuit on this research is being pursued by a team of researchers lead by Dr.
Brady Bundy and myself, including Jeremy Hunt, Amin Saheli, Andrew Broadbent and Matthew
Schinn. Jeremy and Amin are pursuing the next hurdle of the minimal tRNA set, specifically
expression, purification, characterization and optimization. Andrew is pursuing the expression and
characterization of orthogonal aaRS/tRNA pairs. Matthew Schinn is pursuing the expression of
proteins using the synthetic minimal set and the orthogonal aaRS/tRNA pairs.
The potential ability to reassign native codons and expand the protein code by up to 43
uAAs has promising applications in effectively every space of protein biology, such as medical
therapeutics, protein engineering, and microbiological diagnostics.
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8

CONCLUSIONS AND FUTURE WORK

The results reported in this work demonstrate the utility and versatility of CFPS for protein
and bioengineering. We have added to and improved the tool of CFPS by demonstrating a robust
lyophilized system and improved fermentation conditions for systems requiring exogenous
elements. We have laid clear foundations for multiple applications of CFPS, including the rapid
production of recombinant vaccines, novel nanoparticles, site-specific protein immobilization
techniques and an expanded protein code.
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9

APPENDIX A. SUPPLEMENTARY MATERIAL FOR CHAPTER 2

9.1

9.1.1

Resuspension Volume Calculations – Cell Extracts

DC™ Assay Results
Prior to lyophilization, DC™ assays (Bio-Rad, Hercules, California) were employed to

estimate the protein content of the cell extracts. Figure 9-1 depicts the results from an assay using
bovine serum albumin (BSA) as a standard. Equation 9-1 was derived from a regression of the
data in Figure 9-1. OD750 was measured for serial dilutions of extract and the approximate protein
content was estimated using Equation 9-1. The untreated aqueous extract was estimated to contain

BSA [mg/mL]

72 mg/mL protein.

2
1.5
1
0.5
0

R² = 0.9933

0

0.1

0.2

0.3

OD750
Figure 9-1 - DC™ Assay Employing BSA as a Standard. Example of DC™ assay analysis that provides a
standard relationship between protein concentration and OD750. This analysis was performed according to the
manufacturer’s specifications (Bio-Rad, Hercules, California) using bovine serum albumin (BSA) as the
protein standard.
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Equation 9-1 – Estimate Extract Protein Content

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 �
9.1.2

𝑚𝑚𝑚𝑚
𝑚𝑚𝑚𝑚
𝑚𝑚𝑚𝑚
� = 8.8656 �
� × 𝑂𝑂𝑂𝑂750 − 0.7825 � �
𝑚𝑚𝑚𝑚
𝑚𝑚𝑚𝑚 × 𝑂𝑂𝑂𝑂750
𝑚𝑚𝑚𝑚

Water Loss during Lyophilization

Equation 9-2A was used to estimate the amount of water loss during lyophilization. The
density of the water (ρH2O) was calculated as detailed in Equation 9-2C. The density of extract was
calculated from direct extract volume and weight measurements. Protein density (ρprotein) was
estimated using the DC™ assay results (Equation 9-1). Sucrose and Energy mix densities (ρsucrose
and ρenergy mix, respectively) were directly calculated based on their respective known constituents.
Equation 9-2 – Estimate Percentage Water Loss During Lyophilization

A
B
C

%𝐻𝐻2 𝑂𝑂 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 =

∆𝑚𝑚𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
𝑚𝑚𝐻𝐻2𝑂𝑂

𝑚𝑚𝐻𝐻2𝑂𝑂 = 𝜌𝜌𝐻𝐻2𝑂𝑂 × 𝑣𝑣𝑣𝑣𝑣𝑣𝑒𝑒𝑒𝑒𝑒𝑒
𝜌𝜌𝐻𝐻2𝑂𝑂 = 𝜌𝜌𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 − 𝜌𝜌𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 − 𝜌𝜌𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 − 𝜌𝜌𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑚𝑚𝑚𝑚𝑚𝑚

9.1.3 Rehydration Ratios

Lyophilized extracts must be rehydrated prior to use in an aqueous reaction. To obtain a
proper extract rehydration ration (mL water per gram lyophilized extract) for lyophilized extracts,
standard lyophilized extract was rehydrated with the rehydration ratio (Ratiorehydration) of 10.5 mL
water per gram powder as an initial estimate. This solution was subsequently subjected to DC™
assay analysis and estimated to contain 62 mg/mL protein (ρrehydration). A simple calculation using
Equation 9-3A indicated that an appropriate extract rehydration ratio of standard lyophilized
extract was 9 mL water per gram powder.
Lyophilized extracts that were supplemented with sucrose or an energy mix required
individual rehydration ratios. These ratios were calculated as specified in Equation 9-3B and C for
extract supplemented with sucrose and energy mix, respectively. Sucrose was added to the extract
94

at 0.1 gram per 10 mL extract. The additional volume of sucrose was considered negligible. The
energy mix was added as an aqueous solution at a 1-to-1 ratio to extract. The calculated rehydration
ratios for sucrose and energy mix supplemented extracts was 6.21 and 6.51 mL water per gram
powder, respectively.
Equation 9-3 – Rehydration Ratios (RR)

A
B
C

9.2

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑅𝑅𝑅𝑅 �

𝑚𝑚𝑚𝑚
𝑔𝑔

�=

𝜌𝜌𝑟𝑟𝑟𝑟ℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 ×𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑟𝑟𝑟𝑟ℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦

𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑅𝑅𝑅𝑅 =

𝜌𝜌𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
1

1
+𝜌𝜌𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑅𝑅𝑅𝑅𝐸𝐸𝐸𝐸𝐸𝐸

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑀𝑀𝑀𝑀𝑀𝑀 + 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑅𝑅𝑅𝑅 =

1

𝜌𝜌𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑚𝑚𝑚𝑚𝑚𝑚
1
+
2×𝑅𝑅𝑅𝑅𝐸𝐸𝐸𝐸𝐸𝐸
2

CFPS Yield Error due to Rehydration
To estimate the error in the CFPS yields caused by inaccuracies in weighing and

rehydrating the lyophilized extracts, 5x aliquots of xSTDlyo were rehydrated and used with the
same cell-free reaction premix lacking extract. The standard deviation between these reactions was
attributed to errors in weighing and rehydration and included as a portion of the error found in
Figure 9-1.

9.3

Bacterial Contamination
Preparation of cell extracts for cell-free protein synthesis begins with bacterial fermentation

and subsequent lysis. This lysis is thorough, at 99.9996% for the system employed in this work
(49). However, the pre-lysis concentration of cells is near 600 billion cells per mL solution, leaving
about 2 million cells per mL after lysis. Therefore, there is a risk of extracts being degraded by
bacterial growth, particularly at temperatures conducive to bacterial replication. To examine this
risk, the amount of contamination was measured based on colonies formed per µL extract plated
on sterile LB Miller Agar plates. By 14 days, aqueous extract was too contaminated to be
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quantified properly. In contrast, lyophilized extracts showed comparatively lowered
contamination. This reduction in contamination is potentially caused by the lyophilization process.
Another possible cause of reduced contamination is the hyper-salinity of the lyophilized extracts.
As the extracts are dried, the salts from the buffers become exceedingly concentrated, reaching
concentrations that cause cell death.

Figure 9-2 – Bacterial Contamination in Aqueous and Rehydrated Lyophilized Extract. Aqueous and
rehydrated extracts were diluted into an appropriate amount of SOC media, of which 200 µL was plated on
sterile LB Miller Agar plates. Plates were incubated at 37oC for 16-24 hours, at which time the colonies were
counted using ImageJ software (148). Aqueous extract for day 14 and 30 produced a total bacterial lawn on the
plate (>200-fold dilution). Error bars are 20% of the measured value, n=1.

9.4

9.4.1

Powdered Energy Systems

Energy System Selection
Five energy systems were considered for development as powdered energy systems: 1)

phosphoenolpyruvate system (14), 2) creatine-phosphate/creatine-kinase system (211), 3) the
“cytomim” system (15), 4) fructose-1,6-bisphosphate system (7), and 5) glucose system (13). A
powdered PEP-based system (ePEPpow) based upon the aqueous PEP-based system (ePEPaqu) was
developed to serve as a direct comparison. In efforts to establish a potentially more stable energy
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system, the other systems were examined for the stability of their individual components. A
glucose based system (eGLUpow) was selected based upon the high stability of the main energy
source, namely glucose.

9.4.2

Hydration Volumes for Energy Systems
The amount of water to be added to the powder energy systems (called here the “hydration

volume”) was estimated using Equation 9-4. Ideally, the final density of the solution of hydrated
powder should be the same as the density of aqueous energy systems (ρfinal). The volume of the
powder components in the final solution must be considered to prevent excessive dilution. Thus,
the density of the dry powder was measured (ρpowder) and void fraction (φ) of the powder was
assumed to be 1/3.
Equation 9-4 – Hydration Volume

𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 𝒗𝒗𝒗𝒗𝒗𝒗𝒗𝒗𝒗𝒗𝒗𝒗 = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑝𝑝𝑝𝑝𝑝𝑝𝒅𝒅𝒅𝒅𝒅𝒅 �
9.4.3

1

𝜌𝜌𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓

−

1
�
𝜌𝜌𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 (1 − 𝜑𝜑)

pH Optimization of Phosphoenolpyruvate Energy Systems

The ePEPpow energy system is not readily brought to an optimal pH in its powdered format.
Therefore, after dissolving the powder in water, it was necessary to adjust the pH. Due to the small
volumes being optimized, this challenge was addressed through the addition of varying volumes
of 5M NaOH. Figure 9-3 depicts the results of increasing levels of NaOH, with an optimum at
approximately 192 mM NaOH in the final energy mix. Small volumes of these energy mixes were
placed on litmus paper for rough comparisons of pH (acidic to basic corresponding to red to green,
respectively). The optimum pH corresponded to neutral or slightly acidic. When no NaOH is
added, the white coloring on the litmus paper is undissolved PEP.
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The differences in pH and protein yield between optimized ePEPpow and ePEPaqu indicate
that the aqueous system may not be pH optimized. To test this concept, HCl was added to ePEPaqu
and examining the CFPS results, depicted in Figure 9-4. The apparent optimum for this work is
near 10-15 mM HCl.

Figure 9-3 – pH Optimization of Powdered PEP-based Energy System. NaOH was added at increasing levels
to the ePEPpow energy system, sampled on litmus paper and added to cell-free reactions. For the litmus paper,
red is acidic, green is basic, and the mustard yellow is neutral pH. The white coloring on the litmus paper for 0
mM NaOH is undissolved PEP. Error bars represent one standard deviation and n=3.

GFP Yield (RFU)

150
100
50
0

0 mM

10 mM

15 mM

20 mM

HCl Concentration
Figure 9-4 - pH Optimization of Aqueous PEP-based Energy System. HCl was added at increasing levels to
ePEPaqu prior to its use in CFPS reactions. Reactions with HCl added outperformed the control reaction (0 mM
HCl). GFP Yield was normalized to unaltered ePEPaqu yields. Error bars represent one standard deviation with
n=3.
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Harvest Time (hr)
MOPs
eCFPS Temperature (o C)
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Figure 10-1 - Cell-free Protein Synthesis Yields in μg Protein per mL Cell-free Reaction. Average yields
(μg/mL) of nTotal=4 reactions (nextracts=2, neCFPS=2) is given in large font with one standard deviation given in
small font. Protein yields have been colorized as with higher yields corresponding to darker shades of color as
follows: GFP=blue, pPaGFP=red, and CalB=Green.
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CalB in NP

CalB in pOFX

Figure 10-2 - Graphical Soluble and Total Yields for CalB. Average soluble [black] and total [grey] yields
(μg/mL) of nTotal=4 reactions (nextracts=2, neCFPS=2). Comparing pOFX to the NP [no plasmid] system, the average
increase in soluble percentage of CalB is over 350%.
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Activity

100%
50%
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Commercial CalB

CFPS CalB

Figure 10-3 - Activity of Commercial and CFPS-produced CalB. The activity of CalB produced in a pOFX
extract system was compared to the activity of a commercially available CalB (Sigma Aldrich). Activity was
determined using methods previously described, with the following modifications (2). CFPS-produced enzyme
was purified via strep-tag affinity, dialyzed against PBS buffer, concentrated in Amicon Ultra concentrators,
and quantified using scintillation as described previously (79). Initial concentration of assays were 0.05 mM pnitrophenol palmitate, 0.14 M Tris-HCl, 0.14 M NaCl, 4% vol/vol ethanol, and 2.4 ng per mL enzyme. The
change in absorbance of 405 nm was monitored for 1 hour. n=7 for commercial CalB, n=6 for CFPS CalB.
Error bars represent one standard deviation. The activity of the commercial CalB was normalized to 100%.

Figure 10-4 - SDS PAGE of Extracts and Example Densitometry. Uniform amounts (0.5 µL each) of the pEVOL
and pOFX extracts were analyzed using SDS PAGE on 10% Bis-Tris gels in MOPs-SDS running buffer and
ImageJ software (148). The gels of NP (A), pEVOL (B) and pOFX (C) stained with SimplyBlue™ SafeStain
(Invitrogen) revealed overexpression of pEVOL and GroEL/ES, respectively. Gel lanes are laid out by harvest
time and presence or absence of MOPs during fermentation as follows: Lanes 1-6 were growth without MOPs,
lanes 7-12 were grown with MOPs. Lane 1, 2, and 3 are 3, 4.5 and 6 hour harvest, respectively, and this pattern
is continued through lane 12. The initial unnumbered lane is the P7710S prestained protein ladder (New
England Biolabs). To analyze the protein density at a given molecular weight in each extract, a densitometry
map was made for each lane, as exemplified in (D), which represents lane 7 of pOFX. Peaks were selected for
analysis across harvest times, such as the peak for GroEL (Peak 4), GroES (Peak 14), and peaks estimated to
be associated with the ribosomal proteins (Peaks 10 and 11) (212). Peak intensities were measured and
compared across extracts. (E) The graph displays example trends of protein peak intensities within a single
fermentation processed at different harvest times, in this case lanes 7 and 9 of pOFX. There is no single or clear
trend amongst the different proteins, rather some proteins increase, some decrease, and some remain at
approximately the same densities. This lack of distinct trends complicates the identification of direct
correlations between individual protein densities and overall extract viability. NOTE: Lane 3 of (A) had no
sample loaded.
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Figure 11-1 - Linear Regression of Total A2 Protein Production Against A2 Plasmid Concentration. The
production data of A2 Protein being co-expressed with coat protein. A2 plasmid concentration was varied while
the total plasmid concentration (A2 and CP) remained at 12 nM.

Figure 11-2 - Dynamic Light Scattering Data of the Qβ VLP with A2 incorporated. A 90Plus Particle Size
Analyzer was used to measure the diameter of the VLP produced from the CFPS reaction with 1:10 molar ratio
of A2:CP plasmids . As illustrated above, the mean diameter was measured as 29.8 nm ± 6.6 nm (n=10 – one
minute runs, ± 1 standard deviation).
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Conditions
Temp (oC)

Qβ VLP without A2
50 mM DTT 7 mM H2O2
46 56.8 70 46 56.8 70

Qβ VLP with A2
50 mM DTT 7 mM H2O2
46 56.8 70 46 56.8 70

Protein
(Commassie
stained)

VLP

Nucleic Acid
(Ethidium
Bromide
Stained)

VLP
Nucl.
Acid

Figure 11-3 - Agarose Gel Electrophoresis of Qβ VLP Demonstrating Thermal Stability. The VLP were
produced, assembled, purified and concentrated as described. The A2-protein:Coat-protein plasmid ratios
were 0:1 (left) and 1:5 (right). VLP were incubated for 60 mins at room temperature in 50 mM DTT or 7 mM
H2O2. Reactions were then heated with a thermocycler to 46, 56.8 or 70 oC for 5 mins before being cooled to 4
o
C. The 1% agarose gel (0.001% ethidium bromide) was run at a constant 18 volts f7or 2.5 hours before staining
with commassie stain.
350

Billion VLP Adsorbed

300
250

VLP Adsorption
Coat Protein VLPs
A2:Coat Protein VLPs

200
150
100
50
0
Adsorbed VLP

Figure 11-4 - Qβ VLP adsorption onto E. coli F pili. VLPs produced, purified, and concentrated as described
in Materials and Methods at A2:CP plasmid ratios of 0:1 and 1:5. Following the methods for phage adsorption
demonstrated previously ( Tsukada, et al. Biochem Biophy J, 2009), VLP were incubated with excess cells of E.
coli strain CHS 124 (an F` strain) for 60 mins at 37oC. Samples were then filtered through a syringe-driven 0.2
μm polyvinylidene difluoride membrane filter (ThermoFisher). VLP concentration was quantified using
radioactivity measurements.
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3 nm

3 nm

5 nm

Fluorescence (a.u.)

Figure 12-1 - Crystal Structure of sfGFP-related Protein. The potential implications of the residue location
for unnatural amino acid incorporation were investigated using the known crystal structure of a superfolder
green fluorescent protein variant closely related to the pPaGFP (pdbID 2B3P).(213) In the Fig. S1, the betabarrel (dark green) is approximated as a cylinder with the loop of interest (pink) extending from the main
body. The pink loop contains the location for the unnatural amino acid incorporation (black).
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Figure 12-2 - Aminoacyl-tRNA Synthetase Optimization. Cell-free protein synthesis allows for direct access to
the synthesis environment, enabling optimization and maximization of synthesis cofactors. To maximize the
unnatural amino acid incorporation, the effect of different concentrations of aminoacyl-tRNA synthetase and
magnesium glutamate on the production of active pPaGFP was assessed.
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Figure 12-3 - Scintillation and Fluorescence for Washes after pPaGFP Immobilization. To ensure that the
proteins were not remaining in solution or non-specifically binding to the magnetic beads, the beads were
washed 3 times using a PBS-Tween buffer. Each wash consisted of isolating the magnetic beads, removing the
supernatant, and resuspending the beads in 100 μL PBS-Tween buffer. The final suspension (labeled “Beads”)
was in 100 μL PBS and was vortexed directly prior to analysis for a uniform suspension of beads. Displayed
above are the results from liquid scintillation and fluorescence analysis of supernantant from washes 2 and 3,
along with the final suspension containing beads. During the washing process, the unclicked pPaGFP was
removed to background or statistically insignificant levels. For the control reactions containing no copper, the
resuspended beads contained no or insignificant levels of pPaGFP. The prewash and wash 1 results were
removed to provide appropriate scaling. Error bars = standard deviation, n=2.
2

CuSO4
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Figure 12-4 - Freeze-thaw Activity for Free pPaGFP in Copper-containing Solutions. Free pPaGFP was
incubated under the same conditions as bead-immobilized pPaGFP and then was left in its respective reaction
solution. The unbound pPaGFP was subjected to multiple freeze-thaw cycles (squares) or incubated at 4 oC
(diamonds) and assayed for activity. Each freeze-thaw cycle consisted of an incubation for 20 min at -80 oC
followed by a 20 min incubation at room temperature. Samples left unfrozen were maintained at 4 oC for 40
min between assays. The results suggest that incubation with copper plays little role in terms of stability during
freeze-thaw cycles. Error bars = standard deviation, n=2.
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